,author,author_name,candidate,candidate_name,label,similarity
6676,"Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J","Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J",1,0.9046209
8383,"Byrne , LM Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Byrne, LM","Guo , W Deep-Learning-Based Surrogate Model Thermal Signature Prediction Laser Metal Deposition Laser metal deposition ( LMD ) additive manufacturing method metal parts using focused thermal energy fuse materials deposited . LMD , transient thermal signatures in-situ thermal images melt pool , contain rich information process performance . Early prediction transient thermal signatures provides opportunities process monitoring defect prevention . physics-based models LMD conventionally used thermal signature prediction , limitations computationally expensive real-time prediction . scalable , efficient data-science-based model therefore needed . paper develops deep-learning-based surrogate model , called LMD-cGAN , predict emulate transient thermal signatures LMD . model generates images thermal dynamics melt pool conditionally deposition layer . enables early prediction future-layer thermal signatures in-process part based early-layer thermal signatures . respect physics LMD , physics-guided image selection ( PGIS ) mechanism integrated LMD-cGAN calibrate predictions physical benchmarks transient melt pool process . effectiveness efficiency proposed method demonstrated case study LMD Ti-4Al-6V thin-walled structures . Note Practitioners���With online sensing , many LMD applications real-time process data convey valuable information process status part quality . proposed method leverages data thermal signature prediction . LMD-cGAN deep-learning-based surrogate model learns population profile real thermal signatures generates thermal signatures . proposed PGIS mechanism LMD-cGAN ensures physical validity predictions benchmarking physical insights process . LMD-cGAN applied predict thermal signatures future layers based early-layer thermal signatures in-process part ( implicit assumption in-process part predicted type ) . LMD-cGAN also applied emulate thermal signatures specific layers . generate thermal signatures generic , non-defect parts , training data selected caution ��� part data collected obvious defects , thermal signatures generated LMD-cGAN show regular thermal dynamics . Compared pure physical models , proposed method incorporates process uncertainties captured early-layer data , hence ���on-the-fly��� emulation melt pool , characterizing inherent relationship LMD process thermal signatures . 2023 laser metal deposition thermal images surrogate model generative adversarial net physics-guided image generation S. Guo L. Bian . B. Guo","Guo, W",0,0.84923315
12080,"Gordon , B Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Southwell , AL Hayden , MR","Gordon, B","Wu , H Diagnostic value alpha-fetoprotein , Lens culinaris agglutinin-reactive alpha-fetoprotein , des-gamma-carboxyprothrombin hepatitis B virus-related hepatocellular carcinoma Objective study aimed explore use different combinations alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive AFP ( AFP-L3 ) , des-gamma-carboxyprothrombin ( DCP ) early diagnosis hepatocellular carcinoma ( HCC ) patients hepatitis B virus ( HBV ) -associated liver cirrhosis ( LC ) . Methods 167 subjects , including 100 HCC 67 LC , enrolled study . Serum AFP , AFP-L3 , DCP levels detected chemiluminescent enzyme immunoassay analyzed using receiver operating characteristics ( ROC ) method . Results sensitivity specificity AFP DCP differentiating early HCC HBV-associated LC 51.5 % 92.5 % , 60.0 % 84.7 % , respectively . Comparative analysis ROC curves showed significant difference area curve ( AUC ) AFP DCP . Moreover , combination AFP DCP showed largest AUC value diagnostic sensitivity specificity 67 % 83.1 % , respectively . Conclusion results suggest AFP best single biomarker distinguishing HBV-associated LC early HCC induced HBV . However , combination AFP DCP enhance diagnostic value AFP differentiating diseases . None hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin lens culinaris agglutinin-reactive alpha-fetoprotein early diagnosis liver cirrhosis Song , Wang , Su , B Zeng , WP Jiang , TY Zhang , Sun , GZ","Wu, H",0,0.9322201
11992,"Banos , Raul Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Banos, Raul","Shapiro , JI Oxidized HDL , Adipokines , Endothelial Dysfunction : Potential Biomarker Profile Cardiovascular Risk Women Obesity Objective High BMI predicts adverse cardiovascular outcomes positively correlates increased levels adipokines . relationship among BMI , IL-6 , TNF alpha , adiponectin , oxidized high-density lipoprotein ( Ox-HDL ) circulating endothelial cells ( CECs ) endothelial progenitor cells ( EPCs ) well studied . Elevated CEC levels described humans mice obesity diabetes . Ox-HDL shown potent driver adipogenesis vivo vitro . study , elevated BMI examined 2 groups women studied Brooklyn , New York , Huntington , West Virginia , respectively . Methods Twenty-six females obesity five lean controls without overt cardiovascular disease enrolled , 13 Huntington 13 Brooklyn . Cytokine levels , EPCs , CECs determined . Results Females obesity elevated levels leptin , IL-6 , Ox-HDL , increased CEC levels , decreased EPC adiponectin levels ( P < 0.01 ) . Ox-HDL levels higher women Brooklyn versus Huntington ( P < 0.01 ) , possibly higher TNF alpha levels Brooklyn higher adiponectin levels Huntington . Seventy-five percent variance Ox-HDL levels could predicted population ( P < 0.01 ) . Conclusions study reveals unique inflammatory biomarker profile females obesity . 2019.0 Peterson , SJ Thompson , E Singh , Liu , L Weingarten , JA O'Hanlon , K Bialczak , Bhesania , SR Abraham , NG","Shapiro, JI",0,0.95081246
241,"Z. Chen DNN Deployment , Task Offloading , Resource Allocation Joint Task Inference IIoT Joint task inference , fully utilizes end edge cloud cooperation , effectively enhance performance deep neural network ( DNN ) inference services industrial internet things ( IIoT ) applications . paper , propose novel joint resource management scheme multi task multi service scenario consisting multiple sensors , cloud server , base station equipped edge server . time slotted system model proposed , incorporating DNN deployment , data size control , task offloading , computing resource allocation , wireless channel allocation . Among , DNN deployment deploy proper DNNs edge server total resource constraint , data size control make trade task inference accuracy task transmission delay changing task da ta size . goal minimize total cost including total task processing delay total error inference penalty guaranteeing long term task queue stability task inference accuracy requirements . Leveraging Lyapunov optimization , first transform optimization problem deterministic problem time slot . , deep deterministic policy gradient ( DDPG ) based deep reinforcement learning ( DRL ) algorithm designed provide near optimal solution . desi gn fast numerical method data size control sub problem reduce training complexity DRL model , design penalty mechanism prevent frequent optimizations DNN deployment . Extensive experiments conducted varying differen crucial parameters . superiority scheme demonstrated comparison 3 schemes . 2023 deep neural network ( dnn ) inference edge computing industrial internet things ( iiot ) resource management task offloading W. Fan Z. Hao Y. Su F. Wu B. Tang Y. Liu",Z. Chen,"H. Chaoui Developing Online Data-Driven State Health Estimation Lithium-Ion Batteries Random Sensor Measurement Unavailability Data-driven approaches demonstrated remarkable accuracy battery���s state health ( SOH ) estimation ; however , susceptible data quality quantity . Therefore , accurate data-based battery health estimation method highly desirable unreliable industry environment sensors��� random measurements unavailability ubiquitous . Successful training random data unavailability becomes difficult task undertake . Therefore , main challenge offline trained model reliable accurate random sensors��� measurements unavailability . article develops accurate SOH estimation model based nonlinear autoregressive exogenous inputs recurrent neural network lithium-ion batteries whose features��� measurements subjected different random missing observations . evoke uncertainty sensors��� measurements online health diagnostic , missing observation occurrence addressed randomly eliminating sample data evaluating model available measurements . Therefore , require imputation strategy missing values . accuracy estimator model guaranteed extracted underlying features fused adding exponential moving average health features . experimental results two different datasets , Oxford Toyota , different battery chemistry working operations demonstrate mean absolute errors ( MAEs ) RMSs well bounded 2.70 % 3.10 % different random data missing rates 1 % ���30 % . promising prediction model numerous industrial applications high probability random data unavailability . 2023 lithium-ion batteries ( libs ) nonlinear autoregressive exogenous input ( narx ) random measurement unavailability state health ( soh ) estimation S. Bamati",H. Chaoui,0,0.9130754
8173,"Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J","A. Mckiernan One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Bowers D. S. Boning",A. Mckiernan,0,0.82453895
8322,"Zetterberg , Henrik Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Wild , EJ","Zetterberg, Henrik","Zetterberg , H Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Johnson , EB Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Wild , EJ","Zetterberg, H",1,0.93420553
12426,"Potluri , Nalini Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Potluri, Nalini","P. Kothnur Modeling Optimizing Impact Process Equipment Parameters Sputtering Deposition Systems Using Gaussian Process Machine Learning Framework present method empirically modeling optimizing variations sputtering deposition processes using Gaussian Process ( GP ) machine learning methods . predictive models trained limited training data enable rapid sputtering process tuning . first case , model effect process recipe parameters chamber pressure power sputtered film thickness uniformity . second challenging case also demonstrated : modeling film thickness spatial uniformity function equipment configuration parameters . effects chamber configuration variables complex , motivating incorporation prior process knowledge GP framework utilizing physics-based solver . adjusting equipment configuration parameters obtaining corresponding wafer fabrication data costly , key metric expected number tunes required process constraints met . Using past experimental data , show tunes using GP-based predictive model expected converge significantly fewer iterations compared tunes using polynomial , gradient boosted regression tree , multivariate spline , deep learning based modeling methods . 2022 compact modeling deposition gaussian process machine learning modeling optimization process modeling non-uniformity reinforcement learning thickness sputtering uniformity variations C. I. Lang A. Jansen S. Didari D. S. Boning",P. Kothnur,0,0.8096987
9279,"Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K","Sodhi , Komal Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Dao , B Tirona , MT Thompson , E","Sodhi, Komal",1,0.9735406
11789,"Hayden , MR Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Banos , R Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Southwell , AL","Hayden, MR","Hayden , Michael R Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Sandhu , Aly , AE Black , HF Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR","Hayden, Michael R",1,0.92803806
3669,"A. Mckiernan One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Bowers D. S. Boning",A. Mckiernan,"A. Borghesi Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning M. Molan M. Milano A. Bartolini",A. Borghesi,0,0.93386006
460,"Wenhao Fan DNN Deployment , Task Offloading , Resource Allocation Joint Task Inference IIoT Joint task inference , fully utilizes end edge cloud cooperation , effectively enhance performance deep neural network ( DNN ) inference services industrial internet things ( IIoT ) applications . paper , propose novel joint resource management scheme multi task multi service scenario consisting multiple sensors , cloud server , base station equipped edge server . time slotted system model proposed , incorporating DNN deployment , data size control , task offloading , computing resource allocation , wireless channel allocation . Among , DNN deployment deploy proper DNNs edge server total resource constraint , data size control make trade task inference accuracy task transmission delay changing task da ta size . goal minimize total cost including total task processing delay total error inference penalty guaranteeing long term task queue stability task inference accuracy requirements . Leveraging Lyapunov optimization , first transform optimization problem deterministic problem time slot . , deep deterministic policy gradient ( DDPG ) based deep reinforcement learning ( DRL ) algorithm designed provide near optimal solution . desi gn fast numerical method data size control sub problem reduce training complexity DRL model , design penalty mechanism prevent frequent optimizations DNN deployment . Extensive experiments conducted varying differen crucial parameters . superiority scheme demonstrated comparison 3 schemes . 2023 deep neural network ( dnn ) inference edge computing industrial internet things ( iiot ) resource management task offloading Z. Chen Z. Hao Y. Su F. Wu B. Tang Y. Liu",Wenhao Fan,"Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R",0,0.83710325
5565,"Georgiou-Karistianis , N Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Wijeratne , PA Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Poudel , GR Mohan , Sampaio , C Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC","Georgiou-Karistianis, N","H. Wang Mobility Digital Twin : Concept , Architecture , Case Study , Future Challenges Digital Twin digital replica living nonliving physical entity , emerging technology attracted extensive attention different industries past decade . Although Digital Twin studies conducted transportation domain recently , systematic research holistic framework connecting various mobility entities together . study , mobility digital twin ( MDT ) framework developed , defined artificial intelligence ( AI ) -based data-driven cloud���edge���device framework mobility services . MDT consists three building blocks physical space ( namely , Human , Vehicle , Traffic ) , associated Digital Twins digital space . example cloud���edge architecture built Amazon Web Services ( AWS ) accommodate proposed MDT framework fulfill digital functionalities storage , modeling , learning , simulation , prediction . case study personalized adaptive cruise control ( P-ACC ) system conducted , integrates key microservices three digital building blocks MDT framework : 1 ) Human Digital Twin user management driver type classification ; 2 ) Vehicle Digital Twin cloud-based advanced driver-assistance systems ( ADAS ) ; 3 ) Traffic Digital Twin traffic flow monitoring variable speed limit . Future challenges proposed MDT framework discussed toward end article , including standardization , AI computing , public private cloud service , network heterogeneity . 2022 amazon web services ( aws ) cloud computing connected vehicles digital twin edge computing Z. Wang R. Gupta K. Han A. Ganlath N. Ammar P. Tiwari",H. Wang,0,0.8679851
7092,"D.C. Alexander Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",D.C. Alexander,"A. Bartolini ExaMon-X : Predictive Maintenance Framework Automatic Monitoring Industrial IoT Systems recent years , Industrial Internet Things ( IIoT ) led significant steps forward many industries , thanks exploitation several technologies , ranging Big Data processing artificial intelligence ( AI ) . Among various IIoT scenarios , large-scale data centers reap significant benefits adopting Big Data analytics AI-boosted approaches since technologies allow effective predictive maintenance . However , off-the-shelf currently available solutions ideally suited high-performance computing ( HPC ) context , e.g. , sufficiently take account heterogeneous data sources privacy issues hinder adoption cloud solution , fully exploit computing capabilities available loco supercomputing facility . article , tackle issue , propose IIoT holistic vertical framework predictive maintenance supercomputers . framework based big lightweight data monitoring infrastructure , specialized databases suited heterogeneous data , set high-level AI-based functionalities tailored HPC actors��� specific needs . present deployment assess usage framework several in-production HPC systems . 2023 artificial intelligence ( ai ) high-performance computing industrial iot industry 4.0 predictive maintenance A. Borghesi A. Burrello",A. Bartolini,0,0.8122951
9171,"Dao , B Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Tirona , MT Thompson , E Sodhi , K","Dao, B","Edminster , Sarah P. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Harrington , MG","Edminster, Sarah P.",0,0.91731143
955,"Bo Hu Deployment-Efficient Energy Management Strategy Connected Hybrid Electric Vehicle Based Offline Reinforcement Learning development recent artificial intelligence technology , especially great success AlphaGo , growing interest applying reinforcement learning ( RL ) solve energy management strategy ( EMS ) problems hybrid electric vehicles . However , issues current RL algorithms including deployment inefficiency , safety constraint , simulation-to-real gap make inapplicable many industrial EMS tasks . mind considering fact exists many suboptimal EMS controllers generate plentiful amounts interactive data containing informative behaviors , offline RL training framework tries extract policies maximum possible utility available offline data proposed . Furthermore , connected vehicle technology standard many new cars , rather bringing data storage analytics , scheduled training framework put forward . cloud-based approach alleviates computational burden edge devices , also importantly provides deployment-efficient solution EMS tasks adapt changes driving cycle . evaluate effectiveness proposed algorithm real controllers , hardware-in-the-loop ( HIL ) test performed superiority proposed algorithm contrast dynamic programming , behavior cloning , rule-based , vanilla off-policy RL algorithms given . 2022 connected deployment-efficient energy management strategy ( ems ) hybrid electric vehicle ( hev ) offline reinforcement learning ( rl ) J. Li",Bo Hu,"A. Bartolini ExaMon-X : Predictive Maintenance Framework Automatic Monitoring Industrial IoT Systems recent years , Industrial Internet Things ( IIoT ) led significant steps forward many industries , thanks exploitation several technologies , ranging Big Data processing artificial intelligence ( AI ) . Among various IIoT scenarios , large-scale data centers reap significant benefits adopting Big Data analytics AI-boosted approaches since technologies allow effective predictive maintenance . However , off-the-shelf currently available solutions ideally suited high-performance computing ( HPC ) context , e.g. , sufficiently take account heterogeneous data sources privacy issues hinder adoption cloud solution , fully exploit computing capabilities available loco supercomputing facility . article , tackle issue , propose IIoT holistic vertical framework predictive maintenance supercomputers . framework based big lightweight data monitoring infrastructure , specialized databases suited heterogeneous data , set high-level AI-based functionalities tailored HPC actors��� specific needs . present deployment assess usage framework several in-production HPC systems . 2023 artificial intelligence ( ai ) high-performance computing industrial iot industry 4.0 predictive maintenance A. Borghesi A. Burrello",A. Bartolini,0,0.940133
6098,"Heselgrave , Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Heselgrave, A","Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N",0,0.9538925
10361,"Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN","Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN",1,0.8360251
7250,"F.B . Rodrigues Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",F.B. Rodrigues,"Rodrigues , F B Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Rodrigues, F B",1,0.91508186
9316,"Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K","Burckett-St Laurent , David Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison Higham , Helen","Burckett-St Laurent, David",0,0.8755853
11410,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN","A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,1,0.8869579
6329,"McColgan , Peter Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","McColgan, Peter","Tirona , Maria Tria Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Dao , B Thompson , E Sodhi , K","Tirona, Maria Tria",0,0.9086802
814,"H. Chaoui Developing Online Data-Driven State Health Estimation Lithium-Ion Batteries Random Sensor Measurement Unavailability Data-driven approaches demonstrated remarkable accuracy battery���s state health ( SOH ) estimation ; however , susceptible data quality quantity . Therefore , accurate data-based battery health estimation method highly desirable unreliable industry environment sensors��� random measurements unavailability ubiquitous . Successful training random data unavailability becomes difficult task undertake . Therefore , main challenge offline trained model reliable accurate random sensors��� measurements unavailability . article develops accurate SOH estimation model based nonlinear autoregressive exogenous inputs recurrent neural network lithium-ion batteries whose features��� measurements subjected different random missing observations . evoke uncertainty sensors��� measurements online health diagnostic , missing observation occurrence addressed randomly eliminating sample data evaluating model available measurements . Therefore , require imputation strategy missing values . accuracy estimator model guaranteed extracted underlying features fused adding exponential moving average health features . experimental results two different datasets , Oxford Toyota , different battery chemistry working operations demonstrate mean absolute errors ( MAEs ) RMSs well bounded 2.70 % 3.10 % different random data missing rates 1 % ���30 % . promising prediction model numerous industrial applications high probability random data unavailability . 2023 lithium-ion batteries ( libs ) nonlinear autoregressive exogenous input ( narx ) random measurement unavailability state health ( soh ) estimation S. Bamati",H. Chaoui,"Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R",0,0.8506744
584,"Y. Su Joint Task Offloading Resource Allocation Accuracy-Aware Machine-Learning-Based IIoT Applications Machine learning ( ML ) plays key role Intelligent Industrial Internet Things ( IIoT ) applications . Processing computation-intensive ML tasks largely enhanced applying edge computing ( EC ) traditional cloud-based schemes . System optimizations existing works always ignore inference accuracy ML models different complexities , impacts error task inference . article , propose joint task offloading resource allocation scheme accuracy-aware machine-learning-based IIoT applications edge���cloud-based network architecture . aim minimizing long-term average system cost affected task offloading , computing resource allocation , inference accuracy ML models deployed sensors , edge server , cloud server . Lyapunov optimization technique applied convert long-term stochastic optimization problem short-term deterministic problem . optimal algorithm based general Benders decomposition ( GBD ) technology heuristic algorithm based proportional computing resource allocation task offloading strategy comparison proposed efficiently solve problem , respectively . performance scheme proved theoretical analysis evaluated extensive simulations conducted multiple scenarios . Simulation results demonstrate effectiveness superiority two algorithms comparison several schemes proposed existing works . 2023 cloud computing edge computing ( ec ) machine learning ( ml ) resource allocation task offloading W. Fan S. Li J. Liu F. Wu Y. Liu",Y. Su,"Burckett-St Laurent , David Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison Higham , Helen","Burckett-St Laurent, David",0,0.8643489
11415,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN","Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN",1,0.8360251
2341,"H. Wang Mobility Digital Twin : Concept , Architecture , Case Study , Future Challenges Digital Twin digital replica living nonliving physical entity , emerging technology attracted extensive attention different industries past decade . Although Digital Twin studies conducted transportation domain recently , systematic research holistic framework connecting various mobility entities together . study , mobility digital twin ( MDT ) framework developed , defined artificial intelligence ( AI ) -based data-driven cloud���edge���device framework mobility services . MDT consists three building blocks physical space ( namely , Human , Vehicle , Traffic ) , associated Digital Twins digital space . example cloud���edge architecture built Amazon Web Services ( AWS ) accommodate proposed MDT framework fulfill digital functionalities storage , modeling , learning , simulation , prediction . case study personalized adaptive cruise control ( P-ACC ) system conducted , integrates key microservices three digital building blocks MDT framework : 1 ) Human Digital Twin user management driver type classification ; 2 ) Vehicle Digital Twin cloud-based advanced driver-assistance systems ( ADAS ) ; 3 ) Traffic Digital Twin traffic flow monitoring variable speed limit . Future challenges proposed MDT framework discussed toward end article , including standardization , AI computing , public private cloud service , network heterogeneity . 2022 amazon web services ( aws ) cloud computing connected vehicles digital twin edge computing Z. Wang R. Gupta K. Han A. Ganlath N. Ammar P. Tiwari",H. Wang,"Smith , ED Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Banos , R Yanick , C Aly , AE Byrne , LM Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Smith, ED",0,0.83487344
11364,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN","P. Kothnur Modeling Optimizing Impact Process Equipment Parameters Sputtering Deposition Systems Using Gaussian Process Machine Learning Framework present method empirically modeling optimizing variations sputtering deposition processes using Gaussian Process ( GP ) machine learning methods . predictive models trained limited training data enable rapid sputtering process tuning . first case , model effect process recipe parameters chamber pressure power sputtered film thickness uniformity . second challenging case also demonstrated : modeling film thickness spatial uniformity function equipment configuration parameters . effects chamber configuration variables complex , motivating incorporation prior process knowledge GP framework utilizing physics-based solver . adjusting equipment configuration parameters obtaining corresponding wafer fabrication data costly , key metric expected number tunes required process constraints met . Using past experimental data , show tunes using GP-based predictive model expected converge significantly fewer iterations compared tunes using polynomial , gradient boosted regression tree , multivariate spline , deep learning based modeling methods . 2022 compact modeling deposition gaussian process machine learning modeling optimization process modeling non-uniformity reinforcement learning thickness sputtering uniformity variations C. I. Lang A. Jansen S. Didari D. S. Boning",P. Kothnur,0,0.80637276
6639,"Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J","A. Mckiernan One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Bowers D. S. Boning",A. Mckiernan,0,0.8556626
11974,"Banos , Raul Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Banos, Raul","Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J",0,0.9513254
10232,"Edminster , Sarah P. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Harrington , MG","Edminster, Sarah P.","Edminster , SP Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Tran , King , KS Chui , H Pogoda , JM Fonteh , Harrington , MG","Edminster, SP",1,0.9335656
11614,"Shanmugam , NN Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Shanmugam, NN","Wild , EJ Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Wild, EJ",0,0.85717297
4336,"P. Kothnur Modeling Optimizing Impact Process Equipment Parameters Sputtering Deposition Systems Using Gaussian Process Machine Learning Framework present method empirically modeling optimizing variations sputtering deposition processes using Gaussian Process ( GP ) machine learning methods . predictive models trained limited training data enable rapid sputtering process tuning . first case , model effect process recipe parameters chamber pressure power sputtered film thickness uniformity . second challenging case also demonstrated : modeling film thickness spatial uniformity function equipment configuration parameters . effects chamber configuration variables complex , motivating incorporation prior process knowledge GP framework utilizing physics-based solver . adjusting equipment configuration parameters obtaining corresponding wafer fabrication data costly , key metric expected number tunes required process constraints met . Using past experimental data , show tunes using GP-based predictive model expected converge significantly fewer iterations compared tunes using polynomial , gradient boosted regression tree , multivariate spline , deep learning based modeling methods . 2022 compact modeling deposition gaussian process machine learning modeling optimization process modeling non-uniformity reinforcement learning thickness sputtering uniformity variations C. I. Lang A. Jansen S. Didari D. S. Boning",P. Kothnur,"Zlokovic , Berislav , V Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Pogoda , JM Harrington , MG","Zlokovic, Berislav, V",0,0.8181262
6526,"Parker , C Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Parker, C","P. Kothnur Modeling Optimizing Impact Process Equipment Parameters Sputtering Deposition Systems Using Gaussian Process Machine Learning Framework present method empirically modeling optimizing variations sputtering deposition processes using Gaussian Process ( GP ) machine learning methods . predictive models trained limited training data enable rapid sputtering process tuning . first case , model effect process recipe parameters chamber pressure power sputtered film thickness uniformity . second challenging case also demonstrated : modeling film thickness spatial uniformity function equipment configuration parameters . effects chamber configuration variables complex , motivating incorporation prior process knowledge GP framework utilizing physics-based solver . adjusting equipment configuration parameters obtaining corresponding wafer fabrication data costly , key metric expected number tunes required process constraints met . Using past experimental data , show tunes using GP-based predictive model expected converge significantly fewer iterations compared tunes using polynomial , gradient boosted regression tree , multivariate spline , deep learning based modeling methods . 2022 compact modeling deposition gaussian process machine learning modeling optimization process modeling non-uniformity reinforcement learning thickness sputtering uniformity variations C. I. Lang A. Jansen S. Didari D. S. Boning",P. Kothnur,0,0.8354268
12727,"Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R","Banos , Raul Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Banos, Raul",1,0.96069765
12478,"Potluri , Nalini Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Potluri, Nalini","Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG",0,0.91301024
6508,"Parker , C Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Parker, C","S. Wang Trustworthy Localization EM-Based Federated Control Scheme IIoTs Industrial Internet Things ( IIoTs ) significantly changing informative manufacturing pattern smart factories also brings security trustworthiness issue . Concerning trustworthiness issues private preservation tracking systems , hierarchical framework federated control theory designed , consists federated control center , network layer , federated control node . framework combines collaborative Cloud-Edge-End structure machine learning-oriented localization , forms EM-based federated scheme . basis , trustworthy localization model built untrustworthiness probability latent variable . exploring expectation maximization ( EM ) trustworthy localization , local messages aggression equations derived iterative way federated learning . EM-based federated control scheme machine learning-oriented localization finally given . Experiments conducted prove localization accuracy convergence proposed method trustworthiness issue . results show trustworthy localization outperforms traditional methods without considering security threats . 2023 collaborative cloud-edge-end expectation maximization ( em ) federated control industrial internet things ( iiot ) trustworthy localization Z. Wang Z. Zhao M. Sun",S. Wang,0,0.83653945
10857,"Zlokovic , BV Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Zlokovic, BV","Fan Wu DNN Deployment , Task Offloading , Resource Allocation Joint Task Inference IIoT Joint task inference , fully utilizes end edge cloud cooperation , effectively enhance performance deep neural network ( DNN ) inference services industrial internet things ( IIoT ) applications . paper , propose novel joint resource management scheme multi task multi service scenario consisting multiple sensors , cloud server , base station equipped edge server . time slotted system model proposed , incorporating DNN deployment , data size control , task offloading , computing resource allocation , wireless channel allocation . Among , DNN deployment deploy proper DNNs edge server total resource constraint , data size control make trade task inference accuracy task transmission delay changing task da ta size . goal minimize total cost including total task processing delay total error inference penalty guaranteeing long term task queue stability task inference accuracy requirements . Leveraging Lyapunov optimization , first transform optimization problem deterministic problem time slot . , deep deterministic policy gradient ( DDPG ) based deep reinforcement learning ( DRL ) algorithm designed provide near optimal solution . desi gn fast numerical method data size control sub problem reduce training complexity DRL model , design penalty mechanism prevent frequent optimizations DNN deployment . Extensive experiments conducted varying differen crucial parameters . superiority scheme demonstrated comparison 3 schemes . 2023 deep neural network ( dnn ) inference edge computing industrial internet things ( iiot ) resource management task offloading W. Fan Z. Chen Z. Hao Y. Su B. Tang Y. Liu",Fan Wu,0,0.81776065
3213,"R. Jin Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network Z. Chen K. Wu M. Wu X. Li R. Yan",R. Jin,"Riubing Jin Position Encoding Based Convolutional Neural Networks Machine Remaining Useful Life Prediction Accurate remaining useful life ( RUL ) prediction important industrial systems . prevents machines working failure conditions , ensures industrial system works reliably efficiently . Recently , many deep learning based methods proposed predict RUL . Among methods , recurrent neural network ( RNN ) based approaches show strong capability capturing sequential information . allows RNN based methods perform better convolutional neural network ( CNN ) based approaches RUL prediction task . paper , question common paradigm argue existing CNN based approaches designed according classic principles CNN , reduces performances . Additionally , capacity capturing sequential information highly affected receptive field CNN , neglected existing CNN based methods . solve problems , propose series new CNNs , show competitive results RNN based methods . Compared RNN , CNN processes input signals parallel temporal sequence easily determined . alleviate issue , position encoding scheme developed enhance sequential information encoded CNN . Hence , proposed position encoding based CNN called PE-Net improved even performs better RNN based methods . Extensive experiments conducted C-MAPSS dataset , PE-Net shows state-of-the-art performance . 2022 convolutional neural network ( cnn ) deep learning position encoding remaining useful life prediction M. Wu K. Wu K. Gao Z. Chen X. Li",Riubing Jin,1,0.9626891
7083,"D.C. Alexander Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",D.C. Alexander,"Wenhao Fan DNN Deployment , Task Offloading , Resource Allocation Joint Task Inference IIoT Joint task inference , fully utilizes end edge cloud cooperation , effectively enhance performance deep neural network ( DNN ) inference services industrial internet things ( IIoT ) applications . paper , propose novel joint resource management scheme multi task multi service scenario consisting multiple sensors , cloud server , base station equipped edge server . time slotted system model proposed , incorporating DNN deployment , data size control , task offloading , computing resource allocation , wireless channel allocation . Among , DNN deployment deploy proper DNNs edge server total resource constraint , data size control make trade task inference accuracy task transmission delay changing task da ta size . goal minimize total cost including total task processing delay total error inference penalty guaranteeing long term task queue stability task inference accuracy requirements . Leveraging Lyapunov optimization , first transform optimization problem deterministic problem time slot . , deep deterministic policy gradient ( DDPG ) based deep reinforcement learning ( DRL ) algorithm designed provide near optimal solution . desi gn fast numerical method data size control sub problem reduce training complexity DRL model , design penalty mechanism prevent frequent optimizations DNN deployment . Extensive experiments conducted varying differen crucial parameters . superiority scheme demonstrated comparison 3 schemes . 2023 deep neural network ( dnn ) inference edge computing industrial internet things ( iiot ) resource management task offloading Z. Chen Z. Hao Y. Su F. Wu B. Tang Y. Liu",Wenhao Fan,0,0.8351111
10145,"Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ","Margetts , Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Margetts, S",0,0.85666716
7955,"Paulsen , JS Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Johnson , EB Gregory , Georgiou-Karistianis , N Scahill , RI Tabrizi , SJ Alexander , DC","Paulsen, JS","P.A . Wijeratne Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Poudel , GR Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC",P.A. Wijeratne,0,0.9543456
9997,"Edminster , SP Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Tran , King , KS Chui , H Pogoda , JM Fonteh , Harrington , MG","Edminster, SP","Edminster , Sarah P. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Harrington , MG","Edminster, Sarah P.",1,0.9335656
9416,"Lakhani , HV Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Tirona , MT Sodhi , K Thompson , E","Lakhani, HV","Harrington , Michael G. Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Harrington, Michael G.",0,0.8517497
2734,"Z. Wang Partial Transfer Learning Multidiscriminator Deep Weighted Adversarial Network Cross-Machine Fault Diagnosis Deep transfer learning provides feasible fault diagnosis method intelligent mechanical systems . However , method usually assumes source domain target domain label space , greatly limits application actual industry . Therefore , article proposes multidiscriminator deep weighted adversarial network ( MDWAN ) method , especially suitable partial transfer learning number target domain categories less source domain . proposed method mainly composed three parts : feature extractor , multidiscriminator , classifier . feature extraction section , deep separable convolutional neural network model ( DSC ) proposed , greatly reduce parameter calculation amount premise ensuring extraction accuracy . multidiscriminator section , multidiscriminator weighted learning strategy proposed . strategy comprehensively considers domain information source domain label information , introduces weight function quantify contribution source domain samples domain discriminator classifier , effectively identify filter outlier source samples promote positive transfer shared samples . order verify effectiveness feasibility proposed method , method applied three types bearing datasets different machines . Comparing classification results different methods , conclusion shows method beneficial bearing fault classification . 2022 adversarial network cross-machine fault diagnosis multidiscriminator partial transfer learning J. Cui W. Cai Y. Li",Z. Wang,"S. Wu Image Reconstruction Based Multilevel Densely Connected Network Threshold Electrical Capacitance Tomography Electrical capacitance tomography ( ECT ) real-time monitoring technology visualization industrial dynamic processes . Due inherent nonlinearity ill-posed nature ECT inverse problem , achieving fast accurate image reconstruction remains great challenge . novel multilevel densely connected network channelwise thresholds ( MDCN-CW ) proposed , adopts deep-learning framework implement reconstruction process similar iterative algorithms . MDCN-CW highly condensed framework achieves efficient information transfer dense connections within subnetworks , soft thresholding inserted subnetwork nonlinear transformation layer eliminate unimportant features . Matching purpose structure MDCN-CW , phased strategy used train . subnetwork first trained stepwise individual strategy , network parameters fine-tuned subnetworks integrated improve overall fit model . Simulation experimental results show , compared existing deep-learning-based reconstruction methods traditional algorithms , proposed ECT image reconstruction network soft thresholds advantages simple structure , high imaging accuracy , good generalization ability . 2022 channelwise threshold deep learning dense connection electrical capacitance tomography ( ect ) image reconstruction Z. Wang L. Zhang B. Zhang J. Zhao",S. Wu,0,0.9423291
10348,"Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN","A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,1,0.9326489
12843,"Hayden , Michael R Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Sandhu , Aly , AE Black , HF Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR","Hayden, Michael R","Hayden , MR Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Banos , R Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Southwell , AL","Hayden, MR",1,0.92803806
13953,"Bowness , James Simeon Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Bowness, James Simeon","K. . A. Gamage Stacked Machine Deep Learning-Based Approach Analysing Electricity Theft Smart Grids role electricity theft detection ( ETD ) critical maintain cost-efficiency smart grids . However , existing methods theft detection struggle handle large electricity consumption datasets missing values , data variance nonlinear data relationship problems , lack integrated infrastructure coordinating electricity load data analysis procedures . help address problems , simple yet effective ETD model developed . Three modules combined proposed model . first module deploys combination data imputation , outlier handling , normalization class balancing algorithms , enhance time series characteristics generate better quality data improved training learning classifiers . Three different machine learning ( ML ) methods , uncorrelated skillful problem different ways , employed base learning model . Finally , recently developed deep learning approach , namely temporal convolutional network ( TCN ) , used ensemble outputs ML algorithms improved classification accuracy . Experimental results confirm proposed framework yields highly-accurate , robust classification performance , comparison well-established machine deep learning models thus practical tool electricity theft detection industrial applications . 2022 electricity theft detection big data preprocessing data classification smart grid I. U. Khan N. Javeid C. J. Taylor X.",K. A. A. Gamage,0,0.85787344
6658,"Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J","Wild , EJ Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Wild, EJ",1,0.9131129
11298,"Harrington , Michael G. Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Harrington, Michael G.","Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG",1,0.86274064
7145,"D.C. Alexander Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",D.C. Alexander,"Alexander , DC Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Johnson , EB Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ","Alexander, DC",1,0.9527864
9757,"A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,"Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N",1,0.9432736
2105,"Z. Zhao Trustworthy Localization EM-Based Federated Control Scheme IIoTs Industrial Internet Things ( IIoTs ) significantly changing informative manufacturing pattern smart factories also brings security trustworthiness issue . Concerning trustworthiness issues private preservation tracking systems , hierarchical framework federated control theory designed , consists federated control center , network layer , federated control node . framework combines collaborative Cloud-Edge-End structure machine learning-oriented localization , forms EM-based federated scheme . basis , trustworthy localization model built untrustworthiness probability latent variable . exploring expectation maximization ( EM ) trustworthy localization , local messages aggression equations derived iterative way federated learning . EM-based federated control scheme machine learning-oriented localization finally given . Experiments conducted prove localization accuracy convergence proposed method trustworthiness issue . results show trustworthy localization outperforms traditional methods without considering security threats . 2023 collaborative cloud-edge-end expectation maximization ( em ) federated control industrial internet things ( iiot ) trustworthy localization Z. Wang S. Wang M. Sun",Z. Zhao,"Smith , ED Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Banos , R Yanick , C Aly , AE Byrne , LM Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Smith, ED",0,0.824643
11295,"Harrington , Michael G. Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Harrington, Michael G.","Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ",1,0.8365591
8198,"Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J","Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J",1,0.9046209
6804,"A. Heslegrave Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Zetterberg , H Wild , EJ",A. Heslegrave,"Lakhani , HV Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Tirona , MT Sodhi , K Thompson , E","Lakhani, HV",0,0.9149897
2861,"R. Yan Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network R. Jin Z. Chen K. Wu M. Wu X. Li",R. Yan,"A. Samolov Intelligent Optimization Dosing Uniformity Ion Implantation Systems Spatial dose non-uniformity key variation concern ion implantation . non-uniformities often compensated adjusting implantation times spent point wafer : areas low uncompensated dose assigned implantation time , greater dose assigned reduced times . paper , present machine learning based method rapidly learns set compensating implantation times order achieve desired uniformity.We propose iterative tuning approach comprised two components . first component empirical Bayesian forward model infers relationship implantation times implantation dose profile . model updated new implantations performed measured , enabling progressive accuracy improvements tuning . second component optimization method selects compensating times solving constrained optimization problem . tuning process , alternate two components , repeatedly selecting compensating times , measuring resulting dose profile updating model desired uniformity achieved . proposed method compared conventional non-Bayesian industry method record , converges desired uniformity significantly fewer iterations . Finally , solutions found method result greater total dose given total implantation time uniformity , increasing throughput implantation added cost . 2022 doping dose ion implantation kalman filter machine learning modeling optimization spatial tuning uniformity C. I. Lang R. Sprenkle E. Wilson D. S. Boning",A. Samolov,0,0.9067682
3786,"A. Bowers One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Mckiernan D. S. Boning",A. Bowers,"Andrea Bartolini Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning A. Borghesi M. Molan M. Milano",Andrea Bartolini,0,0.93040365
8927,"Sodhi , Komal Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Dao , B Tirona , MT Thompson , E","Sodhi, Komal","Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K",1,0.9735406
9653,"Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N","Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN",1,0.88008475
13521,"Vasalauskaite , Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Noble , J Alison Higham , Helen","Vasalauskaite, A","Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J",0,0.88746756
6074,"Heselgrave , Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Heselgrave, A","A. Heslegrave Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Zetterberg , H Wild , EJ",A. Heslegrave,1,0.91280365
11409,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN","Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N",1,0.88008475
3185,"Z. Chen Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network R. Jin K. Wu M. Wu X. Li R. Yan",Z. Chen,"Bowness , James Simeon Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Bowness, James Simeon",0,0.8866302
669,"Guo , W Deep-Learning-Based Surrogate Model Thermal Signature Prediction Laser Metal Deposition Laser metal deposition ( LMD ) additive manufacturing method metal parts using focused thermal energy fuse materials deposited . LMD , transient thermal signatures in-situ thermal images melt pool , contain rich information process performance . Early prediction transient thermal signatures provides opportunities process monitoring defect prevention . physics-based models LMD conventionally used thermal signature prediction , limitations computationally expensive real-time prediction . scalable , efficient data-science-based model therefore needed . paper develops deep-learning-based surrogate model , called LMD-cGAN , predict emulate transient thermal signatures LMD . model generates images thermal dynamics melt pool conditionally deposition layer . enables early prediction future-layer thermal signatures in-process part based early-layer thermal signatures . respect physics LMD , physics-guided image selection ( PGIS ) mechanism integrated LMD-cGAN calibrate predictions physical benchmarks transient melt pool process . effectiveness efficiency proposed method demonstrated case study LMD Ti-4Al-6V thin-walled structures . Note Practitioners���With online sensing , many LMD applications real-time process data convey valuable information process status part quality . proposed method leverages data thermal signature prediction . LMD-cGAN deep-learning-based surrogate model learns population profile real thermal signatures generates thermal signatures . proposed PGIS mechanism LMD-cGAN ensures physical validity predictions benchmarking physical insights process . LMD-cGAN applied predict thermal signatures future layers based early-layer thermal signatures in-process part ( implicit assumption in-process part predicted type ) . LMD-cGAN also applied emulate thermal signatures specific layers . generate thermal signatures generic , non-defect parts , training data selected caution ��� part data collected obvious defects , thermal signatures generated LMD-cGAN show regular thermal dynamics . Compared pure physical models , proposed method incorporates process uncertainties captured early-layer data , hence ���on-the-fly��� emulation melt pool , characterizing inherent relationship LMD process thermal signatures . 2023 laser metal deposition thermal images surrogate model generative adversarial net physics-guided image generation S. Guo L. Bian . B. Guo","Guo, W","Pereira , DG Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Sodhi , K Thompson , E","Pereira, DG",0,0.83691454
8525,"Lowe , AJ Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Lowe, AJ","K. . A. Gamage Stacked Machine Deep Learning-Based Approach Analysing Electricity Theft Smart Grids role electricity theft detection ( ETD ) critical maintain cost-efficiency smart grids . However , existing methods theft detection struggle handle large electricity consumption datasets missing values , data variance nonlinear data relationship problems , lack integrated infrastructure coordinating electricity load data analysis procedures . help address problems , simple yet effective ETD model developed . Three modules combined proposed model . first module deploys combination data imputation , outlier handling , normalization class balancing algorithms , enhance time series characteristics generate better quality data improved training learning classifiers . Three different machine learning ( ML ) methods , uncorrelated skillful problem different ways , employed base learning model . Finally , recently developed deep learning approach , namely temporal convolutional network ( TCN ) , used ensemble outputs ML algorithms improved classification accuracy . Experimental results confirm proposed framework yields highly-accurate , robust classification performance , comparison well-established machine deep learning models thus practical tool electricity theft detection industrial applications . 2022 electricity theft detection big data preprocessing data classification smart grid I. U. Khan N. Javeid C. J. Taylor X.",K. A. A. Gamage,0,0.7981139
4004,"J. Ruth One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili P. Cardillo P. Alfred A. Bowers A. Mckiernan D. S. Boning",J. Ruth,"Higham , Helen Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Burckett-St Laurent , David Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison","Higham, Helen",0,0.87418044
5968,"Wild , EJ Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Wild, EJ","Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J",1,0.9367704
1833,"B. Cline Physical Unclonable Function Systems Based Pattern Transfer Fingerprint-Like Patterns letter , demonstrate physical unclonable function ( PUF ) system based fingerprint-like random planar structures pattern transfer self-assembled binary polymer mixtures . properly designed electrode structures materials , different types conductance distributions large variations achieved , allowing PUF function differential on/off modes . uniqueness PUF verified inter Hamming distance entropy different temperatures . PUF shown resistant machine learning attack based Fourier extrapolation . proposed fingerprint PUF compatible back-end-of-line ( BEOL ) process offers potential hardware security primitive IoT industry . 2022 puf hardware security phase separation dual-mode function Z. Wang X. Zhu S. Jeloka W. D. Lu",B. Cline,"Foiani , MS Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Johnson , EB Arridge , De Vita , E Scahill , RI Heslegrave , Zetterberg , H Wild , EJ","Foiani, MS",0,0.8143439
3123,"Z. Chen Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network R. Jin K. Wu M. Wu X. Li R. Yan",Z. Chen,"Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J",0,0.8733074
1677,"W. D. Lu Physical Unclonable Function Systems Based Pattern Transfer Fingerprint-Like Patterns letter , demonstrate physical unclonable function ( PUF ) system based fingerprint-like random planar structures pattern transfer self-assembled binary polymer mixtures . properly designed electrode structures materials , different types conductance distributions large variations achieved , allowing PUF function differential on/off modes . uniqueness PUF verified inter Hamming distance entropy different temperatures . PUF shown resistant machine learning attack based Fourier extrapolation . proposed fingerprint PUF compatible back-end-of-line ( BEOL ) process offers potential hardware security primitive IoT industry . 2022 puf hardware security phase separation dual-mode function Z. Wang X. Zhu S. Jeloka B. Cline",W. D. Lu,"Z. Chen Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network R. Jin K. Wu M. Wu X. Li R. Yan",Z. Chen,0,0.9022936
12213,"Anderson , LM Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Gordon , B Southwell , AL Hayden , MR","Anderson, LM","Schobel , Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Scahill , RI Heslegrave , Zetterberg , H Wild , EJ","Schobel, S",0,0.9221286
2880,"R. Yan Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network R. Jin Z. Chen K. Wu M. Wu X. Li",R. Yan,"P.A . Wijeratne Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Poudel , GR Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC",P.A. Wijeratne,0,0.9008419
5669,"Poudel , GR Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Wijeratne , PA Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC","Poudel, GR","Guo , W Deep-Learning-Based Surrogate Model Thermal Signature Prediction Laser Metal Deposition Laser metal deposition ( LMD ) additive manufacturing method metal parts using focused thermal energy fuse materials deposited . LMD , transient thermal signatures in-situ thermal images melt pool , contain rich information process performance . Early prediction transient thermal signatures provides opportunities process monitoring defect prevention . physics-based models LMD conventionally used thermal signature prediction , limitations computationally expensive real-time prediction . scalable , efficient data-science-based model therefore needed . paper develops deep-learning-based surrogate model , called LMD-cGAN , predict emulate transient thermal signatures LMD . model generates images thermal dynamics melt pool conditionally deposition layer . enables early prediction future-layer thermal signatures in-process part based early-layer thermal signatures . respect physics LMD , physics-guided image selection ( PGIS ) mechanism integrated LMD-cGAN calibrate predictions physical benchmarks transient melt pool process . effectiveness efficiency proposed method demonstrated case study LMD Ti-4Al-6V thin-walled structures . Note Practitioners���With online sensing , many LMD applications real-time process data convey valuable information process status part quality . proposed method leverages data thermal signature prediction . LMD-cGAN deep-learning-based surrogate model learns population profile real thermal signatures generates thermal signatures . proposed PGIS mechanism LMD-cGAN ensures physical validity predictions benchmarking physical insights process . LMD-cGAN applied predict thermal signatures future layers based early-layer thermal signatures in-process part ( implicit assumption in-process part predicted type ) . LMD-cGAN also applied emulate thermal signatures specific layers . generate thermal signatures generic , non-defect parts , training data selected caution ��� part data collected obvious defects , thermal signatures generated LMD-cGAN show regular thermal dynamics . Compared pure physical models , proposed method incorporates process uncertainties captured early-layer data , hence ���on-the-fly��� emulation melt pool , characterizing inherent relationship LMD process thermal signatures . 2023 laser metal deposition thermal images surrogate model generative adversarial net physics-guided image generation S. Guo L. Bian . B. Guo","Guo, W",0,0.87024665
8728,"Singh , Oxidized HDL , Adipokines , Endothelial Dysfunction : Potential Biomarker Profile Cardiovascular Risk Women Obesity Objective High BMI predicts adverse cardiovascular outcomes positively correlates increased levels adipokines . relationship among BMI , IL-6 , TNF alpha , adiponectin , oxidized high-density lipoprotein ( Ox-HDL ) circulating endothelial cells ( CECs ) endothelial progenitor cells ( EPCs ) well studied . Elevated CEC levels described humans mice obesity diabetes . Ox-HDL shown potent driver adipogenesis vivo vitro . study , elevated BMI examined 2 groups women studied Brooklyn , New York , Huntington , West Virginia , respectively . Methods Twenty-six females obesity five lean controls without overt cardiovascular disease enrolled , 13 Huntington 13 Brooklyn . Cytokine levels , EPCs , CECs determined . Results Females obesity elevated levels leptin , IL-6 , Ox-HDL , increased CEC levels , decreased EPC adiponectin levels ( P < 0.01 ) . Ox-HDL levels higher women Brooklyn versus Huntington ( P < 0.01 ) , possibly higher TNF alpha levels Brooklyn higher adiponectin levels Huntington . Seventy-five percent variance Ox-HDL levels could predicted population ( P < 0.01 ) . Conclusions study reveals unique inflammatory biomarker profile females obesity . 2019.0 Peterson , SJ Shapiro , JI Thompson , E Liu , L Weingarten , JA O'Hanlon , K Bialczak , Bhesania , SR Abraham , NG","Singh, S","Taylor , Alasdair Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Taylor, Alasdair",0,0.88566965
10399,"Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG","B. Cline Physical Unclonable Function Systems Based Pattern Transfer Fingerprint-Like Patterns letter , demonstrate physical unclonable function ( PUF ) system based fingerprint-like random planar structures pattern transfer self-assembled binary polymer mixtures . properly designed electrode structures materials , different types conductance distributions large variations achieved , allowing PUF function differential on/off modes . uniqueness PUF verified inter Hamming distance entropy different temperatures . PUF shown resistant machine learning attack based Fourier extrapolation . proposed fingerprint PUF compatible back-end-of-line ( BEOL ) process offers potential hardware security primitive IoT industry . 2022 puf hardware security phase separation dual-mode function Z. Wang X. Zhu S. Jeloka W. D. Lu",B. Cline,0,0.8027747
5233,"Wu , H Diagnostic value alpha-fetoprotein , Lens culinaris agglutinin-reactive alpha-fetoprotein , des-gamma-carboxyprothrombin hepatitis B virus-related hepatocellular carcinoma Objective study aimed explore use different combinations alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive AFP ( AFP-L3 ) , des-gamma-carboxyprothrombin ( DCP ) early diagnosis hepatocellular carcinoma ( HCC ) patients hepatitis B virus ( HBV ) -associated liver cirrhosis ( LC ) . Methods 167 subjects , including 100 HCC 67 LC , enrolled study . Serum AFP , AFP-L3 , DCP levels detected chemiluminescent enzyme immunoassay analyzed using receiver operating characteristics ( ROC ) method . Results sensitivity specificity AFP DCP differentiating early HCC HBV-associated LC 51.5 % 92.5 % , 60.0 % 84.7 % , respectively . Comparative analysis ROC curves showed significant difference area curve ( AUC ) AFP DCP . Moreover , combination AFP DCP showed largest AUC value diagnostic sensitivity specificity 67 % 83.1 % , respectively . Conclusion results suggest AFP best single biomarker distinguishing HBV-associated LC early HCC induced HBV . However , combination AFP DCP enhance diagnostic value AFP differentiating diseases . None hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin lens culinaris agglutinin-reactive alpha-fetoprotein early diagnosis liver cirrhosis Song , Wang , Su , B Zeng , WP Jiang , TY Zhang , Sun , GZ","Wu, H","Wang , J Epigenomic analysis 5-hydroxy-methylcytosine ( 5hmC ) reveals novel DNA methylation markers lung cancers Background : DNA methylation fifth position cytosine ( 5mC ) common epigenetic alteration affecting range cellular processes . recent years , 5-hydroxymethylcytosine ( 5hmC ) , oxidized form 5mC , risen broad interests potential biomarker lung cancer diagnosis survival . Methods : analyzed epigenome-wide 5hmC profiles paired lung tumor adjacent normal tissues , using TET-Assisted Bisulfite ( TAB ) array - Infinium MethylationEPIC BeadChip ( EPIC ) approach . differentially methylated CpG sites identified , biological relevance 5hmC assessed differential methylation regions ( DMR ) analysis gene set analysis ( GSA ) . Results : observed global hypomethylation 5hmC comparing tumor normal tissues , hypermethylated 5hmC enriched CpG islands gene upstream . Comparison 5hmC 5modC ( total methylation : 5mC + 5hmC ) profiling showed low correlation , small proportion significant 5hmC loci overlapped significant total methylation loci . GSA analysis suggested 5hmC mainly involved biological processes cellular process , biological regulation , metabolic process . Conclusion : first study analyze epigenome-wide 5hmC profiles among paired lung tumor normal tissues . observed global hypomethylation 5hmC lung cancers , hypermethylated 5hmC enriched CpG islands gene upstream . found genome-wide 5hmC levels correlate total methylation , GSA suggested different biological functions 5hmC compared 5modC . Overall , results demonstrate potential 5hmC novel biomarker lung cancer . 2020.0 lung neoplasms epigenomics biomarkers methylation 5-hydroxymethylcytosine Wang , ZH Du , ML Yuan , QY Guo , YC Hutchinson , JN Su , L Zheng , YN Mucci , LA Lin , XH Hou , LF Christiani , DC","Wang, J",0,0.91393375
5315,"Su , B Diagnostic value alpha-fetoprotein , Lens culinaris agglutinin-reactive alpha-fetoprotein , des-gamma-carboxyprothrombin hepatitis B virus-related hepatocellular carcinoma Objective study aimed explore use different combinations alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive AFP ( AFP-L3 ) , des-gamma-carboxyprothrombin ( DCP ) early diagnosis hepatocellular carcinoma ( HCC ) patients hepatitis B virus ( HBV ) -associated liver cirrhosis ( LC ) . Methods 167 subjects , including 100 HCC 67 LC , enrolled study . Serum AFP , AFP-L3 , DCP levels detected chemiluminescent enzyme immunoassay analyzed using receiver operating characteristics ( ROC ) method . Results sensitivity specificity AFP DCP differentiating early HCC HBV-associated LC 51.5 % 92.5 % , 60.0 % 84.7 % , respectively . Comparative analysis ROC curves showed significant difference area curve ( AUC ) AFP DCP . Moreover , combination AFP DCP showed largest AUC value diagnostic sensitivity specificity 67 % 83.1 % , respectively . Conclusion results suggest AFP best single biomarker distinguishing HBV-associated LC early HCC induced HBV . However , combination AFP DCP enhance diagnostic value AFP differentiating diseases . None hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin lens culinaris agglutinin-reactive alpha-fetoprotein early diagnosis liver cirrhosis Song , Wang , Zeng , WP Jiang , TY Zhang , Sun , GZ Wu , H","Su, B","Guo , W Deep-Learning-Based Surrogate Model Thermal Signature Prediction Laser Metal Deposition Laser metal deposition ( LMD ) additive manufacturing method metal parts using focused thermal energy fuse materials deposited . LMD , transient thermal signatures in-situ thermal images melt pool , contain rich information process performance . Early prediction transient thermal signatures provides opportunities process monitoring defect prevention . physics-based models LMD conventionally used thermal signature prediction , limitations computationally expensive real-time prediction . scalable , efficient data-science-based model therefore needed . paper develops deep-learning-based surrogate model , called LMD-cGAN , predict emulate transient thermal signatures LMD . model generates images thermal dynamics melt pool conditionally deposition layer . enables early prediction future-layer thermal signatures in-process part based early-layer thermal signatures . respect physics LMD , physics-guided image selection ( PGIS ) mechanism integrated LMD-cGAN calibrate predictions physical benchmarks transient melt pool process . effectiveness efficiency proposed method demonstrated case study LMD Ti-4Al-6V thin-walled structures . Note Practitioners���With online sensing , many LMD applications real-time process data convey valuable information process status part quality . proposed method leverages data thermal signature prediction . LMD-cGAN deep-learning-based surrogate model learns population profile real thermal signatures generates thermal signatures . proposed PGIS mechanism LMD-cGAN ensures physical validity predictions benchmarking physical insights process . LMD-cGAN applied predict thermal signatures future layers based early-layer thermal signatures in-process part ( implicit assumption in-process part predicted type ) . LMD-cGAN also applied emulate thermal signatures specific layers . generate thermal signatures generic , non-defect parts , training data selected caution ��� part data collected obvious defects , thermal signatures generated LMD-cGAN show regular thermal dynamics . Compared pure physical models , proposed method incorporates process uncertainties captured early-layer data , hence ���on-the-fly��� emulation melt pool , characterizing inherent relationship LMD process thermal signatures . 2023 laser metal deposition thermal images surrogate model generative adversarial net physics-guided image generation S. Guo L. Bian . B. Guo","Guo, W",0,0.82255423
5515,"Wang , L Circulating Exosomal miRNA Diagnostic Biomarkers Neurodegenerative Diseases Neurodegenerative diseases ( NDDs ) group diseases caused chronic progressive degeneration neural tissue . main pathological manifestations neuronal degeneration loss brain and/or spinal cord . Common NDDs include Alzheimer disease ( AD ) , Parkinson disease ( PD ) , Huntington disease ( HD ) , amyotrophic lateral sclerosis ( ALS ) . complicated pathological characteristics different clinical manifestations NDDs result lack sensitive efficient diagnostic methods . addition , sensitive biomarkers available monitor course NDDs , predict prognosis , monitor therapeutic response . Despite extensive research recent years , analysis amyloid beta ( beta ) alpha-synuclein failed effectively improve NDD diagnosis . Although recent studies indicated circulating miRNAs promising diagnostic biomarkers NDDs , miRNA peripheral circulation susceptible interference components , making circulating miRNA results less consistent . Exosomes small membrane vesicles diameter approximately 30-100 nm transport proteins , lipids , mRNA , miRNA . recent studies shown exosomes double-membrane structure resist ribonuclease blood , giving exosomal miRNA high stability making resistant degradation , may become ideal biomarker circulating fluids . review , discuss applicability circulating exosomal miRNAs biomarkers , highlight technical aspects exosomal miRNA analysis , review studies used circulating exosomal miRNAs candidate diagnostic biomarkers NDDs . 2020.0 biomarker exosomal mirna neurodegenerative disease csf blood Zhang , LJ","Wang, L","Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG",0,0.8975444
6955,"Scahill , R.I. Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Heslegrave , Zetterberg , H Wild , EJ","Scahill, R.I.","Noble , J Alison Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Burckett-St Laurent , David Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Higham , Helen","Noble, J Alison",0,0.89029866
13450,"Burckett-St Laurent , David Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison Higham , Helen","Burckett-St Laurent, David","Burckett-St Laurent , Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Burckett-St Laurent, D",1,0.97334534
13246,"Noble , J Alison Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Burckett-St Laurent , David Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Higham , Helen","Noble, J Alison","A. Samolov Intelligent Optimization Dosing Uniformity Ion Implantation Systems Spatial dose non-uniformity key variation concern ion implantation . non-uniformities often compensated adjusting implantation times spent point wafer : areas low uncompensated dose assigned implantation time , greater dose assigned reduced times . paper , present machine learning based method rapidly learns set compensating implantation times order achieve desired uniformity.We propose iterative tuning approach comprised two components . first component empirical Bayesian forward model infers relationship implantation times implantation dose profile . model updated new implantations performed measured , enabling progressive accuracy improvements tuning . second component optimization method selects compensating times solving constrained optimization problem . tuning process , alternate two components , repeatedly selecting compensating times , measuring resulting dose profile updating model desired uniformity achieved . proposed method compared conventional non-Bayesian industry method record , converges desired uniformity significantly fewer iterations . Finally , solutions found method result greater total dose given total implantation time uniformity , increasing throughput implantation added cost . 2022 doping dose ion implantation kalman filter machine learning modeling optimization spatial tuning uniformity C. I. Lang R. Sprenkle E. Wilson D. S. Boning",A. Samolov,0,0.8566717
6213,"Rodrigues , F B Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Rodrigues, F B","Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K",0,0.9081137
10469,"Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG","Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ",1,0.9119874
8935,"Sodhi , Komal Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Dao , B Tirona , MT Thompson , E","Sodhi, Komal","Edminster , Sarah P. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Harrington , MG","Edminster, Sarah P.",0,0.9154039
8691,"Singh , Oxidized HDL , Adipokines , Endothelial Dysfunction : Potential Biomarker Profile Cardiovascular Risk Women Obesity Objective High BMI predicts adverse cardiovascular outcomes positively correlates increased levels adipokines . relationship among BMI , IL-6 , TNF alpha , adiponectin , oxidized high-density lipoprotein ( Ox-HDL ) circulating endothelial cells ( CECs ) endothelial progenitor cells ( EPCs ) well studied . Elevated CEC levels described humans mice obesity diabetes . Ox-HDL shown potent driver adipogenesis vivo vitro . study , elevated BMI examined 2 groups women studied Brooklyn , New York , Huntington , West Virginia , respectively . Methods Twenty-six females obesity five lean controls without overt cardiovascular disease enrolled , 13 Huntington 13 Brooklyn . Cytokine levels , EPCs , CECs determined . Results Females obesity elevated levels leptin , IL-6 , Ox-HDL , increased CEC levels , decreased EPC adiponectin levels ( P < 0.01 ) . Ox-HDL levels higher women Brooklyn versus Huntington ( P < 0.01 ) , possibly higher TNF alpha levels Brooklyn higher adiponectin levels Huntington . Seventy-five percent variance Ox-HDL levels could predicted population ( P < 0.01 ) . Conclusions study reveals unique inflammatory biomarker profile females obesity . 2019.0 Peterson , SJ Shapiro , JI Thompson , E Liu , L Weingarten , JA O'Hanlon , K Bialczak , Bhesania , SR Abraham , NG","Singh, S","Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K",0,0.9140402
7633,"Foiani , MS Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Johnson , EB Arridge , De Vita , E Scahill , RI Heslegrave , Zetterberg , H Wild , EJ","Foiani, MS","A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,0,0.9468572
9983,"Edminster , SP Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Tran , King , KS Chui , H Pogoda , JM Fonteh , Harrington , MG","Edminster, SP","Byrne , LM Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Byrne, LM",0,0.9390011
9471,"Pereira , DG Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Sodhi , K Thompson , E","Pereira, DG","A. Mckiernan One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Bowers D. S. Boning",A. Mckiernan,0,0.82659984
9644,"Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N","Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN",1,0.8857805
7848,"Alexander , DC Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Johnson , EB Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ","Alexander, DC","D.C. Alexander Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",D.C. Alexander,1,0.9527864
8527,"Lowe , AJ Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Lowe, AJ","A. Mckiernan One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili J. Ruth P. Cardillo P. Alfred A. Bowers D. S. Boning",A. Mckiernan,0,0.8238684
7975,"Paulsen , JS Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Johnson , EB Gregory , Georgiou-Karistianis , N Scahill , RI Tabrizi , SJ Alexander , DC","Paulsen, JS","Zetterberg , Henrik Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Wild , EJ","Zetterberg, Henrik",0,0.93793523
12024,"Banos , Raul Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Banos, Raul","Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R",1,0.96069765
2768,"Z. Wang Partial Transfer Learning Multidiscriminator Deep Weighted Adversarial Network Cross-Machine Fault Diagnosis Deep transfer learning provides feasible fault diagnosis method intelligent mechanical systems . However , method usually assumes source domain target domain label space , greatly limits application actual industry . Therefore , article proposes multidiscriminator deep weighted adversarial network ( MDWAN ) method , especially suitable partial transfer learning number target domain categories less source domain . proposed method mainly composed three parts : feature extractor , multidiscriminator , classifier . feature extraction section , deep separable convolutional neural network model ( DSC ) proposed , greatly reduce parameter calculation amount premise ensuring extraction accuracy . multidiscriminator section , multidiscriminator weighted learning strategy proposed . strategy comprehensively considers domain information source domain label information , introduces weight function quantify contribution source domain samples domain discriminator classifier , effectively identify filter outlier source samples promote positive transfer shared samples . order verify effectiveness feasibility proposed method , method applied three types bearing datasets different machines . Comparing classification results different methods , conclusion shows method beneficial bearing fault classification . 2022 adversarial network cross-machine fault diagnosis multidiscriminator partial transfer learning J. Cui W. Cai Y. Li",Z. Wang,"Parker , C Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Parker, C",0,0.8437578
9941,"Edminster , SP Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Tran , King , KS Chui , H Pogoda , JM Fonteh , Harrington , MG","Edminster, SP","K. . A. Gamage Stacked Machine Deep Learning-Based Approach Analysing Electricity Theft Smart Grids role electricity theft detection ( ETD ) critical maintain cost-efficiency smart grids . However , existing methods theft detection struggle handle large electricity consumption datasets missing values , data variance nonlinear data relationship problems , lack integrated infrastructure coordinating electricity load data analysis procedures . help address problems , simple yet effective ETD model developed . Three modules combined proposed model . first module deploys combination data imputation , outlier handling , normalization class balancing algorithms , enhance time series characteristics generate better quality data improved training learning classifiers . Three different machine learning ( ML ) methods , uncorrelated skillful problem different ways , employed base learning model . Finally , recently developed deep learning approach , namely temporal convolutional network ( TCN ) , used ensemble outputs ML algorithms improved classification accuracy . Experimental results confirm proposed framework yields highly-accurate , robust classification performance , comparison well-established machine deep learning models thus practical tool electricity theft detection industrial applications . 2022 electricity theft detection big data preprocessing data classification smart grid I. U. Khan N. Javeid C. J. Taylor X.",K. A. A. Gamage,0,0.8084918
11137,"Gibson , GE Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Gibson, GE","Su , B Diagnostic value alpha-fetoprotein , Lens culinaris agglutinin-reactive alpha-fetoprotein , des-gamma-carboxyprothrombin hepatitis B virus-related hepatocellular carcinoma Objective study aimed explore use different combinations alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive AFP ( AFP-L3 ) , des-gamma-carboxyprothrombin ( DCP ) early diagnosis hepatocellular carcinoma ( HCC ) patients hepatitis B virus ( HBV ) -associated liver cirrhosis ( LC ) . Methods 167 subjects , including 100 HCC 67 LC , enrolled study . Serum AFP , AFP-L3 , DCP levels detected chemiluminescent enzyme immunoassay analyzed using receiver operating characteristics ( ROC ) method . Results sensitivity specificity AFP DCP differentiating early HCC HBV-associated LC 51.5 % 92.5 % , 60.0 % 84.7 % , respectively . Comparative analysis ROC curves showed significant difference area curve ( AUC ) AFP DCP . Moreover , combination AFP DCP showed largest AUC value diagnostic sensitivity specificity 67 % 83.1 % , respectively . Conclusion results suggest AFP best single biomarker distinguishing HBV-associated LC early HCC induced HBV . However , combination AFP DCP enhance diagnostic value AFP differentiating diseases . None hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin lens culinaris agglutinin-reactive alpha-fetoprotein early diagnosis liver cirrhosis Song , Wang , Zeng , WP Jiang , TY Zhang , Sun , GZ Wu , H","Su, B",0,0.84314394
10593,"Zlokovic , Berislav , V Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Pogoda , JM Harrington , MG","Zlokovic, Berislav, V","Zlokovic , BV Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Zlokovic, BV",1,0.8632393
6196,"Rodrigues , F B Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Rodrigues, F B","F.B . Rodrigues Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",F.B. Rodrigues,1,0.91508186
8397,"Byrne , LM Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Byrne, LM","H. Wang Mobility Digital Twin : Concept , Architecture , Case Study , Future Challenges Digital Twin digital replica living nonliving physical entity , emerging technology attracted extensive attention different industries past decade . Although Digital Twin studies conducted transportation domain recently , systematic research holistic framework connecting various mobility entities together . study , mobility digital twin ( MDT ) framework developed , defined artificial intelligence ( AI ) -based data-driven cloud���edge���device framework mobility services . MDT consists three building blocks physical space ( namely , Human , Vehicle , Traffic ) , associated Digital Twins digital space . example cloud���edge architecture built Amazon Web Services ( AWS ) accommodate proposed MDT framework fulfill digital functionalities storage , modeling , learning , simulation , prediction . case study personalized adaptive cruise control ( P-ACC ) system conducted , integrates key microservices three digital building blocks MDT framework : 1 ) Human Digital Twin user management driver type classification ; 2 ) Vehicle Digital Twin cloud-based advanced driver-assistance systems ( ADAS ) ; 3 ) Traffic Digital Twin traffic flow monitoring variable speed limit . Future challenges proposed MDT framework discussed toward end article , including standardization , AI computing , public private cloud service , network heterogeneity . 2022 amazon web services ( aws ) cloud computing connected vehicles digital twin edge computing Z. Wang R. Gupta K. Han A. Ganlath N. Ammar P. Tiwari",H. Wang,0,0.8150404
5110,"Hutchinson , JN Epigenomic analysis 5-hydroxy-methylcytosine ( 5hmC ) reveals novel DNA methylation markers lung cancers Background : DNA methylation fifth position cytosine ( 5mC ) common epigenetic alteration affecting range cellular processes . recent years , 5-hydroxymethylcytosine ( 5hmC ) , oxidized form 5mC , risen broad interests potential biomarker lung cancer diagnosis survival . Methods : analyzed epigenome-wide 5hmC profiles paired lung tumor adjacent normal tissues , using TET-Assisted Bisulfite ( TAB ) array - Infinium MethylationEPIC BeadChip ( EPIC ) approach . differentially methylated CpG sites identified , biological relevance 5hmC assessed differential methylation regions ( DMR ) analysis gene set analysis ( GSA ) . Results : observed global hypomethylation 5hmC comparing tumor normal tissues , hypermethylated 5hmC enriched CpG islands gene upstream . Comparison 5hmC 5modC ( total methylation : 5mC + 5hmC ) profiling showed low correlation , small proportion significant 5hmC loci overlapped significant total methylation loci . GSA analysis suggested 5hmC mainly involved biological processes cellular process , biological regulation , metabolic process . Conclusion : first study analyze epigenome-wide 5hmC profiles among paired lung tumor normal tissues . observed global hypomethylation 5hmC lung cancers , hypermethylated 5hmC enriched CpG islands gene upstream . found genome-wide 5hmC levels correlate total methylation , GSA suggested different biological functions 5hmC compared 5modC . Overall , results demonstrate potential 5hmC novel biomarker lung cancer . 2020.0 lung neoplasms epigenomics biomarkers methylation 5-hydroxymethylcytosine Wang , ZH Du , ML Yuan , QY Guo , YC Su , L Zheng , YN Wang , J Mucci , LA Lin , XH Hou , LF Christiani , DC","Hutchinson, JN","P. Kothnur Modeling Optimizing Impact Process Equipment Parameters Sputtering Deposition Systems Using Gaussian Process Machine Learning Framework present method empirically modeling optimizing variations sputtering deposition processes using Gaussian Process ( GP ) machine learning methods . predictive models trained limited training data enable rapid sputtering process tuning . first case , model effect process recipe parameters chamber pressure power sputtered film thickness uniformity . second challenging case also demonstrated : modeling film thickness spatial uniformity function equipment configuration parameters . effects chamber configuration variables complex , motivating incorporation prior process knowledge GP framework utilizing physics-based solver . adjusting equipment configuration parameters obtaining corresponding wafer fabrication data costly , key metric expected number tunes required process constraints met . Using past experimental data , show tunes using GP-based predictive model expected converge significantly fewer iterations compared tunes using polynomial , gradient boosted regression tree , multivariate spline , deep learning based modeling methods . 2022 compact modeling deposition gaussian process machine learning modeling optimization process modeling non-uniformity reinforcement learning thickness sputtering uniformity variations C. I. Lang A. Jansen S. Didari D. S. Boning",P. Kothnur,0,0.79386944
12551,"Aly , AE Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Aly, AE","Hutchinson , JN Epigenomic analysis 5-hydroxy-methylcytosine ( 5hmC ) reveals novel DNA methylation markers lung cancers Background : DNA methylation fifth position cytosine ( 5mC ) common epigenetic alteration affecting range cellular processes . recent years , 5-hydroxymethylcytosine ( 5hmC ) , oxidized form 5mC , risen broad interests potential biomarker lung cancer diagnosis survival . Methods : analyzed epigenome-wide 5hmC profiles paired lung tumor adjacent normal tissues , using TET-Assisted Bisulfite ( TAB ) array - Infinium MethylationEPIC BeadChip ( EPIC ) approach . differentially methylated CpG sites identified , biological relevance 5hmC assessed differential methylation regions ( DMR ) analysis gene set analysis ( GSA ) . Results : observed global hypomethylation 5hmC comparing tumor normal tissues , hypermethylated 5hmC enriched CpG islands gene upstream . Comparison 5hmC 5modC ( total methylation : 5mC + 5hmC ) profiling showed low correlation , small proportion significant 5hmC loci overlapped significant total methylation loci . GSA analysis suggested 5hmC mainly involved biological processes cellular process , biological regulation , metabolic process . Conclusion : first study analyze epigenome-wide 5hmC profiles among paired lung tumor normal tissues . observed global hypomethylation 5hmC lung cancers , hypermethylated 5hmC enriched CpG islands gene upstream . found genome-wide 5hmC levels correlate total methylation , GSA suggested different biological functions 5hmC compared 5modC . Overall , results demonstrate potential 5hmC novel biomarker lung cancer . 2020.0 lung neoplasms epigenomics biomarkers methylation 5-hydroxymethylcytosine Wang , ZH Du , ML Yuan , QY Guo , YC Su , L Zheng , YN Wang , J Mucci , LA Lin , XH Hou , LF Christiani , DC","Hutchinson, JN",0,0.9160051
5888,"P.A . Wijeratne Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Poudel , GR Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC",P.A. Wijeratne,"Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R",0,0.90909487
7139,"D.C. Alexander Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",D.C. Alexander,"Schobel , Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Scahill , RI Heslegrave , Zetterberg , H Wild , EJ","Schobel, S",0,0.99924386
1426,"A. Bartolini ExaMon-X : Predictive Maintenance Framework Automatic Monitoring Industrial IoT Systems recent years , Industrial Internet Things ( IIoT ) led significant steps forward many industries , thanks exploitation several technologies , ranging Big Data processing artificial intelligence ( AI ) . Among various IIoT scenarios , large-scale data centers reap significant benefits adopting Big Data analytics AI-boosted approaches since technologies allow effective predictive maintenance . However , off-the-shelf currently available solutions ideally suited high-performance computing ( HPC ) context , e.g. , sufficiently take account heterogeneous data sources privacy issues hinder adoption cloud solution , fully exploit computing capabilities available loco supercomputing facility . article , tackle issue , propose IIoT holistic vertical framework predictive maintenance supercomputers . framework based big lightweight data monitoring infrastructure , specialized databases suited heterogeneous data , set high-level AI-based functionalities tailored HPC actors��� specific needs . present deployment assess usage framework several in-production HPC systems . 2023 artificial intelligence ( ai ) high-performance computing industrial iot industry 4.0 predictive maintenance A. Borghesi A. Burrello",A. Bartolini,"Andrea Bartolini Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning A. Borghesi M. Molan M. Milano",Andrea Bartolini,1,0.935379
3951,"J. Ruth One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili P. Cardillo P. Alfred A. Bowers A. Mckiernan D. S. Boning",J. Ruth,"Scahill , R.I. Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Heslegrave , Zetterberg , H Wild , EJ","Scahill, R.I.",0,0.85859036
1702,"W. D. Lu Physical Unclonable Function Systems Based Pattern Transfer Fingerprint-Like Patterns letter , demonstrate physical unclonable function ( PUF ) system based fingerprint-like random planar structures pattern transfer self-assembled binary polymer mixtures . properly designed electrode structures materials , different types conductance distributions large variations achieved , allowing PUF function differential on/off modes . uniqueness PUF verified inter Hamming distance entropy different temperatures . PUF shown resistant machine learning attack based Fourier extrapolation . proposed fingerprint PUF compatible back-end-of-line ( BEOL ) process offers potential hardware security primitive IoT industry . 2022 puf hardware security phase separation dual-mode function Z. Wang X. Zhu S. Jeloka B. Cline",W. D. Lu,"Heselgrave , Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Heselgrave, A",0,0.7927625
10124,"Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ","Harrington , Michael G. Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Harrington, Michael G.",1,0.8365591
12380,"Black , Hailey Findlay Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Anderson , LM Gordon , B Southwell , AL Hayden , MR","Black, Hailey Findlay","Black , HF Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Sandhu , Aly , AE Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR Hayden , MR","Black, HF",1,0.94040406
8717,"Singh , Oxidized HDL , Adipokines , Endothelial Dysfunction : Potential Biomarker Profile Cardiovascular Risk Women Obesity Objective High BMI predicts adverse cardiovascular outcomes positively correlates increased levels adipokines . relationship among BMI , IL-6 , TNF alpha , adiponectin , oxidized high-density lipoprotein ( Ox-HDL ) circulating endothelial cells ( CECs ) endothelial progenitor cells ( EPCs ) well studied . Elevated CEC levels described humans mice obesity diabetes . Ox-HDL shown potent driver adipogenesis vivo vitro . study , elevated BMI examined 2 groups women studied Brooklyn , New York , Huntington , West Virginia , respectively . Methods Twenty-six females obesity five lean controls without overt cardiovascular disease enrolled , 13 Huntington 13 Brooklyn . Cytokine levels , EPCs , CECs determined . Results Females obesity elevated levels leptin , IL-6 , Ox-HDL , increased CEC levels , decreased EPC adiponectin levels ( P < 0.01 ) . Ox-HDL levels higher women Brooklyn versus Huntington ( P < 0.01 ) , possibly higher TNF alpha levels Brooklyn higher adiponectin levels Huntington . Seventy-five percent variance Ox-HDL levels could predicted population ( P < 0.01 ) . Conclusions study reveals unique inflammatory biomarker profile females obesity . 2019.0 Peterson , SJ Shapiro , JI Thompson , E Liu , L Weingarten , JA O'Hanlon , K Bialczak , Bhesania , SR Abraham , NG","Singh, S","Black , Hailey Findlay Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Anderson , LM Gordon , B Southwell , AL Hayden , MR","Black, Hailey Findlay",0,0.9284073
10478,"Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG","Harrington , Michael G. Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Harrington, Michael G.",1,0.86274064
1191,"Andrea Bartolini Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning A. Borghesi M. Molan M. Milano",Andrea Bartolini,"A. Bartolini ExaMon-X : Predictive Maintenance Framework Automatic Monitoring Industrial IoT Systems recent years , Industrial Internet Things ( IIoT ) led significant steps forward many industries , thanks exploitation several technologies , ranging Big Data processing artificial intelligence ( AI ) . Among various IIoT scenarios , large-scale data centers reap significant benefits adopting Big Data analytics AI-boosted approaches since technologies allow effective predictive maintenance . However , off-the-shelf currently available solutions ideally suited high-performance computing ( HPC ) context , e.g. , sufficiently take account heterogeneous data sources privacy issues hinder adoption cloud solution , fully exploit computing capabilities available loco supercomputing facility . article , tackle issue , propose IIoT holistic vertical framework predictive maintenance supercomputers . framework based big lightweight data monitoring infrastructure , specialized databases suited heterogeneous data , set high-level AI-based functionalities tailored HPC actors��� specific needs . present deployment assess usage framework several in-production HPC systems . 2023 artificial intelligence ( ai ) high-performance computing industrial iot industry 4.0 predictive maintenance A. Borghesi A. Burrello",A. Bartolini,1,0.935379
12792,"Hayden , Michael R Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Sandhu , Aly , AE Black , HF Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR","Hayden, Michael R","Poudel , GR Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Wijeratne , PA Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC","Poudel, GR",0,0.91103107
10945,"Zlokovic , BV Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Zlokovic, BV","Zlokovic , Berislav , V Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Pogoda , JM Harrington , MG","Zlokovic, Berislav, V",1,0.8632393
5403,"Su , B Diagnostic value alpha-fetoprotein , Lens culinaris agglutinin-reactive alpha-fetoprotein , des-gamma-carboxyprothrombin hepatitis B virus-related hepatocellular carcinoma Objective study aimed explore use different combinations alpha-fetoprotein ( AFP ) , Lens culinaris agglutinin-reactive AFP ( AFP-L3 ) , des-gamma-carboxyprothrombin ( DCP ) early diagnosis hepatocellular carcinoma ( HCC ) patients hepatitis B virus ( HBV ) -associated liver cirrhosis ( LC ) . Methods 167 subjects , including 100 HCC 67 LC , enrolled study . Serum AFP , AFP-L3 , DCP levels detected chemiluminescent enzyme immunoassay analyzed using receiver operating characteristics ( ROC ) method . Results sensitivity specificity AFP DCP differentiating early HCC HBV-associated LC 51.5 % 92.5 % , 60.0 % 84.7 % , respectively . Comparative analysis ROC curves showed significant difference area curve ( AUC ) AFP DCP . Moreover , combination AFP DCP showed largest AUC value diagnostic sensitivity specificity 67 % 83.1 % , respectively . Conclusion results suggest AFP best single biomarker distinguishing HBV-associated LC early HCC induced HBV . However , combination AFP DCP enhance diagnostic value AFP differentiating diseases . None hepatocellular carcinoma alpha-fetoprotein des-gamma-carboxyprothrombin lens culinaris agglutinin-reactive alpha-fetoprotein early diagnosis liver cirrhosis Song , Wang , Zeng , WP Jiang , TY Zhang , Sun , GZ Wu , H","Su, B","Gibson , GE Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Gibson, GE",0,0.84314394
8089,"Johnson , Eileanoir B . Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ Alexander , DC","Johnson, Eileanoir B.","E.B . Johnson Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",E.B. Johnson,1,0.94674736
8192,"Wild , E J Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H","Wild, E J","Wild , EJ Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Wild, EJ",1,0.9367704
10347,"Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN","Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N",1,0.8857805
10117,"Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ","Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG",1,0.9119874
9762,"A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,"Fonteh , Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Chiang , AJ Arakaki , X Edminster , SP Harrington , MG","Fonteh, AN",1,0.9326489
5839,"P.A . Wijeratne Robust Markers Sample Sizes Multicenter Trials Huntington Disease Objective identification sensitive biomarkers essential validate therapeutics Huntington disease ( HD ) . directly compare structural imaging markers across largest collective imaging HD dataset identify set imaging markers robust multicenter variation derive upper estimates sample sizes clinical trials HD . Methods used 1 postprocessing pipeline retrospectively analyze T1-weighted magnetic resonance imaging ( MRI ) scans 624 participants 3 time points , PREDICT-HD , TRACK-HD , IMAGE-HD studies . used mixed effects models adjust regional brain volumes covariates , calculate effect sizes , simulate possible treatment effects disease-affected anatomical regions . used model estimate statistical power possible treatment effects anatomical regions clinical markers . Results identified set common anatomical regions similarly large standardized effect sizes ( > 0.5 ) healthy control premanifest HD ( PreHD ) groups . included subcortical , white matter , cortical regions nonventricular cerebrospinal fluid ( CSF ) . also observed consistent spatial distribution effect size region across whole brain . found multicenter studies necessary capture treatment effect variance ; 20 % treatment effect , power > 80 % achieved caudate ( n = 661 ) , pallidum ( n = 687 ) , nonventricular CSF ( n = 939 ) , , crucially , imaging markers provided greater power standard clinical markers . Interpretation findings provide first cross-study validation structural imaging markers HD , supporting use measurements endpoints observational studies clinical trials . ANN NEUROL 2020 2020.0 Johnson , EB Eshaghi , Aksman , L Gregory , Johnson , HJ Poudel , GR Mohan , Sampaio , C Georgiou-Karistianis , N Paulsen , JS Tabrizi , SJ Scahill , RI Alexander , DC",P.A. Wijeratne,"Scahill , R.I. Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Heslegrave , Zetterberg , H Wild , EJ","Scahill, R.I.",0,0.9459559
13060,"Sandhu , Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Aly , AE Black , HF Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR Hayden , MR","Sandhu, A","Pereira , DG Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Sodhi , K Thompson , E","Pereira, DG",0,0.9199726
13355,"Burckett-St Laurent , David Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison Higham , Helen","Burckett-St Laurent, David","Z. Wang Image Reconstruction Based Multilevel Densely Connected Network Threshold Electrical Capacitance Tomography Electrical capacitance tomography ( ECT ) real-time monitoring technology visualization industrial dynamic processes . Due inherent nonlinearity ill-posed nature ECT inverse problem , achieving fast accurate image reconstruction remains great challenge . novel multilevel densely connected network channelwise thresholds ( MDCN-CW ) proposed , adopts deep-learning framework implement reconstruction process similar iterative algorithms . MDCN-CW highly condensed framework achieves efficient information transfer dense connections within subnetworks , soft thresholding inserted subnetwork nonlinear transformation layer eliminate unimportant features . Matching purpose structure MDCN-CW , phased strategy used train . subnetwork first trained stepwise individual strategy , network parameters fine-tuned subnetworks integrated improve overall fit model . Simulation experimental results show , compared existing deep-learning-based reconstruction methods traditional algorithms , proposed ECT image reconstruction network soft thresholds advantages simple structure , high imaging accuracy , good generalization ability . 2022 channelwise threshold deep learning dense connection electrical capacitance tomography ( ect ) image reconstruction L. Zhang B. Zhang J. Zhao S. Wu",Z. Wang,0,0.8692429
12966,"Black , HF Cerebrospinal fluid biomarkers assessing Huntington disease onset severity identification molecular biomarkers CSF individuals affected Huntington disease may help improve predictions disease onset , better define disease progression could facilitate evaluation potential therapies . primary objective study investigate novel CSF protein candidates replicate previously reported protein biomarker changes CSF Huntington disease mutation carriers healthy controls . secondary objective compare discriminatory potential individual protein analytes combinations CSF protein markers stratifying individuals based severity Huntington disease . conducted hypothesis-driven analysis 26 pre-specified protein analytes CSF 16 manifest Huntington disease subjects , eight premanifest Huntington disease mutation carriers eight healthy control individuals using parallel-reaction monitoring mass spectrometry . addition reproducing reported changes previously investigated CSF biomarkers ( NEFL , PDYN , PENK ) , also identified novel exploratory CSF proteins ( C1QB , CNR1 , GNAL , IDO1 , IGF2 , PPP1R1B ) whose levels altered Huntington disease mutation carriers and/or across stages disease . Moreover , report strong associations select CSF proteins clinical measures disease severity manifest Huntington disease subjects ( C1QB , CNR1 , NEFL , PDYN , PPP1R1B , TTR ) years predicted disease onset premanifest Huntington disease mutation carriers ( ALB , C4B , CTSD , IGHG1 , TTR ) . Using receiver operating characteristic curve analysis , identified PENK discriminant CSF protein stratifying Huntington disease mutation carriers controls . also identified exploratory multi-marker CSF protein panels improved discrimination premanifest Huntington disease mutation carriers controls ( PENK , ALB NEFL ) , early/midstage Huntington disease premanifest mutation carriers ( PPP1R1B , TTR , CHI3L1 , CTSD ) , late-stage early/midstage Huntington disease ( CNR1 , PPP1R1B , BDNF , APOE , IGHG1 ) compared individual CSF proteins . study , demonstrate combinations CSF proteins outperform individual markers stratifying individuals based Huntington disease mutation status disease severity . Moreover , define exploratory multi-marker CSF protein panels , validated , may used improve accuracy disease-onset predictions , complement existing clinical imaging biomarkers monitoring severity Huntington disease , potentially assessing therapeutic response clinical trials . Additional studies CSF collected larger cohorts Huntington disease mutation carriers needed replicate exploratory findings . 2022.0 huntington disease biomarkers csf neurofilament light proenkephalin Caron , NS Haqqani , Sandhu , Aly , AE Bone , JN McBride , JL Abulrob , Stanimirovic , Leavitt , BR Hayden , MR","Black, HF","Black , Hailey Findlay Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Anderson , LM Gordon , B Southwell , AL Hayden , MR","Black, Hailey Findlay",1,0.94040406
7385,"Zetterberg , H Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Johnson , EB Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Wild , EJ","Zetterberg, H","Zetterberg , Henrik Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Wild , EJ","Zetterberg, Henrik",1,0.93420553
13919,"Burckett-St Laurent , Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Taylor , Alasdair Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Burckett-St Laurent, D","Burckett-St Laurent , David Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Noble , J Alison Higham , Helen","Burckett-St Laurent, David",1,0.97334534
7309,"F.B . Rodrigues Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",F.B. Rodrigues,"Noble , J Alison Evaluation impact assistive artificial intelligence ultrasound scanning regional anaesthesia . BACKGROUND : Ultrasound-guided regional anaesthesia relies visualisation key landmark , target , safety structures ultrasound . However , challenging , particularly inexperienced practitioners . Artificial intelligence ( AI ) increasingly applied medical image interpretation , including ultrasound . exploratory study , evaluated ultrasound scanning performance non-experts ultrasound-guided regional anaesthesia , without use assistive AI device.METHODS : Twenty-one anaesthetists , non-experts ultrasound-guided regional anaesthesia , underwent standardised teaching session ultrasound scanning six peripheral nerve blocks . performed scan block ; half scans performed AI assistance half without . Experts assessed acquisition correct block view correct identification sono-anatomical structures view . Participants reported scan confidence , experts provided global rating score scan performance , scans timed.RESULTS : Experts assessed 126 ultrasound scans . Participants acquired correct block view 56/62 ( 90.3 % ) scans device compared 47/62 ( 75.1 % ) without ( P=0.031 , two data points lost ) . Correct identification sono-anatomical structures view 188/212 ( 88.8 % ) device compared 161/208 ( 77.4 % ) without ( P=0.002 ) . significant overall difference participant confidence , expert global performance score , scan time.CONCLUSIONS : Use assistive AI device associated improved ultrasound image acquisition interpretation . technology holds potential augment performance ultrasound scanning regional anaesthesia non-experts , potentially expanding patient access techniques.CLINICAL TRIAL REGISTRATION : NCT05156099 . 2023 Bowness , James Macfarlane , Alan J R Burckett-St Laurent , David Harris , Catherine Margetts , Steve Morecroft , Megan Phillips , David Rees , Tom Sleep , Nick Vasalauskaite , Asta West , Simeon Higham , Helen","Noble, J Alison",0,0.8886524
3331,"Riubing Jin Position Encoding Based Convolutional Neural Networks Machine Remaining Useful Life Prediction Accurate remaining useful life ( RUL ) prediction important industrial systems . prevents machines working failure conditions , ensures industrial system works reliably efficiently . Recently , many deep learning based methods proposed predict RUL . Among methods , recurrent neural network ( RNN ) based approaches show strong capability capturing sequential information . allows RNN based methods perform better convolutional neural network ( CNN ) based approaches RUL prediction task . paper , question common paradigm argue existing CNN based approaches designed according classic principles CNN , reduces performances . Additionally , capacity capturing sequential information highly affected receptive field CNN , neglected existing CNN based methods . solve problems , propose series new CNNs , show competitive results RNN based methods . Compared RNN , CNN processes input signals parallel temporal sequence easily determined . alleviate issue , position encoding scheme developed enhance sequential information encoded CNN . Hence , proposed position encoding based CNN called PE-Net improved even performs better RNN based methods . Extensive experiments conducted C-MAPSS dataset , PE-Net shows state-of-the-art performance . 2022 convolutional neural network ( cnn ) deep learning position encoding remaining useful life prediction M. Wu K. Wu K. Gao Z. Chen X. Li",Riubing Jin,"R. Jin Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network Z. Chen K. Wu M. Wu X. Li R. Yan",R. Jin,1,0.9626891
9639,"Fonteh , Alfred N Alpha desynchronization simple working memory unmasks pathological aging cognitively healthy individuals aim explore cognitive challenge combined objective physiology reveal abnormal frontal alpha event-related desynchronization ( ERD ) , early Alzheimer 's disease ( AD ) . used quantitative electroencephalography ( qEEG ) investigate brain activities N-back working memory ( WM ) processing two different load conditions ( N = 0 2 ) aging cohort . studied 60-100 year old participants , normal cognition , fits one two subgroups cerebrospinal fluid ( CSF ) proteins : cognitively healthy ( CH ) normal amyloid/tau ratio ( CH-NAT , n = 10 ) pathological amyloid/tau ratio ( CH-PAT , n = 14 ) . recorded behavioral performances , analyzed alpha power alpha spectral entropy ( SE ) three occasions : resting state , event-related desynchronization ( ERD ) [ 250 similar 750 ms ] 0-back 2-back . 0-back WM testing , behavioral performance similar two groups , however , qEEG notably differentiated CH-PATs CH-NATs simple , 0-back testing : Alpha ERD decreased baseline parietal region CH-NATs , decreased brain regions CH-PATs . Alpha SE change CH-NATs , increased baseline CH-PATs frontal left lateral regions ( p < 0.01 ) , higher frontal region ( p < 0.01 ) CH-PATs compared CH-NATs . alpha ERD SE analyses suggest frontal lobe dysfunction WM processing CH-PAT stage . Additional power correlations behavioral performance also explored . study provide pilot information evaluate whether biomarker clinical significance . 2019.0 Arakaki , X Lee , R King , KS Harrington , MG","Fonteh, Alfred N","A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,1,0.9432736
11393,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN","E.B . Johnson Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",E.B. Johnson,0,0.90190274
2309,"H. Wang Mobility Digital Twin : Concept , Architecture , Case Study , Future Challenges Digital Twin digital replica living nonliving physical entity , emerging technology attracted extensive attention different industries past decade . Although Digital Twin studies conducted transportation domain recently , systematic research holistic framework connecting various mobility entities together . study , mobility digital twin ( MDT ) framework developed , defined artificial intelligence ( AI ) -based data-driven cloud���edge���device framework mobility services . MDT consists three building blocks physical space ( namely , Human , Vehicle , Traffic ) , associated Digital Twins digital space . example cloud���edge architecture built Amazon Web Services ( AWS ) accommodate proposed MDT framework fulfill digital functionalities storage , modeling , learning , simulation , prediction . case study personalized adaptive cruise control ( P-ACC ) system conducted , integrates key microservices three digital building blocks MDT framework : 1 ) Human Digital Twin user management driver type classification ; 2 ) Vehicle Digital Twin cloud-based advanced driver-assistance systems ( ADAS ) ; 3 ) Traffic Digital Twin traffic flow monitoring variable speed limit . Future challenges proposed MDT framework discussed toward end article , including standardization , AI computing , public private cloud service , network heterogeneity . 2022 amazon web services ( aws ) cloud computing connected vehicles digital twin edge computing Z. Wang R. Gupta K. Han A. Ganlath N. Ammar P. Tiwari",H. Wang,"Johnson , Eileanoir B . Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ Alexander , DC","Johnson, Eileanoir B.",0,0.8632925
6777,"A. Heslegrave Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Zetterberg , H Wild , EJ",A. Heslegrave,"Heselgrave , Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Heselgrave, A",1,0.91280365
7416,"Zetterberg , H Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Johnson , EB Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Wild , EJ","Zetterberg, H","Banos , Raul Mutant Huntingtin Cleared Brain via Active Mechanisms Huntington Disease Huntington disease ( HD ) neurodegenerative disease caused CAG trinucleotide repeat expansion huntingtin ( HTT ) gene . Therapeutics lower HTT shown preclinical promise evaluated clinical trials . However , clinical assessment brain HTT lowering presents challenges . reported mutant HTT ( mHTT ) CSF HD patients correlates clinical measures , including disease burden well motor cognitive performance . also shown lowering HTT brains HD mice results correlative reduction mHTT CSF , prompting use measure exploratory marker target engagement clinical trials . study , investigate mechanisms mHTT clearance brain adult mice sexes elucidate significance therapy-induced CSF mHTT changes . demonstrate , although neurodegeneration increases CSF mHTT concentrations , mHTT also present CSF mice absence neurodegeneration . Importantly , show secretion mHTT cells CNS followed glymphatic clearance extracellular space contributes mHTT CSF . Furthermore , observe secretion wild type HTT healthy control neurons , suggesting HTT secretion normal process occurring absence pathogenesis . Overall , data support passive release active clearance mHTT CSF , suggesting treatment-induced changes may represent combination target engagement preservation neurons . 2021.0 biomarker cerebrospinal fluid glymphatic system huntington disease neurodegeneration protein secretion Caron , NS Yanick , C Aly , AE Byrne , LM Smith , ED Xie , YY Smith , SEP Potluri , N Black , HF Casal , L Ko , Cheung , Kim , H Seong , Wild , EJ Song , JJ Hayden , MR Southwell , AL","Banos, Raul",0,0.9571024
13655,"Taylor , Alasdair Assistive artificial intelligence ultrasound image interpretation regional anaesthesia : external validation study . BACKGROUND : Ultrasonound used identify anatomical structures regional anaesthesia guide needle insertion injection local anaesthetic . ScanNav Anatomy Peripheral Nerve Block ( Intelligent Ultrasound , Cardiff , UK ) artificial intelligence-based device produces colour overlay real-time B-mode ultrasound highlight anatomical structures interest . evaluated accuracy artificial-intelligence colour overlay perceived influence risk adverse events block failure.METHODS : Ultrasound-guided regional anaesthesia experts acquired 720 videos 40 volunteers ( across nine anatomical regions ) without using device . artificial-intelligence colour overlay subsequently applied . Three experts independently reviewed video ( original unmodified video ) assess accuracy colour overlay relation key anatomical structures ( true positive/negative false positive/negative ) potential highlighting modify perceived risk adverse events ( needle trauma nerves , arteries , pleura , peritoneum ) block failure.RESULTS : artificial-intelligence models identified structure interest 93.5 % cases ( 1519/1624 ) , false-negative rate 3.0 % ( 48/1624 ) false-positive rate 3.5 % ( 57/1624 ) . Highlighting judged reduce risk unwanted needle trauma nerves , arteries , pleura , peritoneum 62.9-86.4 % cases ( 302/480 345/400 ) , increase risk 0.0-1.7 % ( 0/160 8/480 ) . Risk block failure reported reduced 81.3 % scans ( 585/720 ) increased 1.8 % ( 13/720 ) .CONCLUSIONS : Artificial intelligence-based devices potentially aid image acquisition interpretation ultrasound-guided regional anaesthesia . studies necessary demonstrate effectiveness supporting training clinical practice.CLINICAL TRIAL REGISTRATION : NCT04906018 . 2023 Bowness , James Burckett-St Laurent , David Hernandez , Nadia Keane , Pearse Lobo , Clara Margetts , Steve Moka , Eleni Pawa , Amit Rosenblatt , Meg Sleep , Nick Woodworth , Glenn Vasalauskaite , Asta Noble , J Alison Higham , Helen","Taylor, Alasdair","Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ",0,0.85552347
7862,"Alexander , DC Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Johnson , EB Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ","Alexander, DC","Sodhi , Komal Detecting early onset anthracyclines-induced cardiotoxicity using novel panel biomarkers West-Virginian population breast cancer Cardiotoxic manifestation associated breast cancer treatment anthracycline regimen increases patients ' susceptibility myocardial injury , reduction left ventricular ejection fraction complications associated heart failure . currently standardized , minimally invasive , cost effective clinically verified procedure monitor cardiotoxicity post-anthracycline therapy initiation , detect early onset irreversible cardiovascular complications . study aims create panel novel biomarkers circulating miRNAs associated cardiotoxicity , assessing correlation cardiac injury specific markers , troponin , demonstrate development cardiac dysfunction breast cancer patients . Blood obtained West Virginian females clinically diagnosed breast cancer receiving anthracyclines showed upregulated level biomarkers circulating miRNAs 3 6 months chemotherapy initiation increased levels cardiac troponin T. biomarkers miRNAs significantly correlated elevated troponins . Following 6 months anthracycline-regimens , 23 % patient population showed cardiotoxicity reduced left ventricular ejection fraction . results support clinical application plasma biomarkers circulating miRNAs develop panel early diagnosis chemotherapy related cardiac dysfunction enable early detection disease progression management irreversible cardiac damage . 2021.0 Lakhani , HV Pillai , SS Zehra , Dao , B Tirona , MT Thompson , E","Sodhi, Komal",0,0.9390436
6759,"A. Heslegrave Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Zetterberg , H Wild , EJ",A. Heslegrave,"J. Ruth One Class Process Anomaly Detection Using Kernel Density Estimation Methods present one-class anomaly detection method uses time series sensor data detect anomalies faults semiconductor fabrication processes . Critically , method trained using small amounts known successful run data , making possible implement many processes recipes without needing example faults . proposed method uses kernel density estimation ( KDE ) create probability distributions sensor values nominal processing . classifying unseen sensor data , determine likelihood arose ( often non-Gaussian ) nominal distribution , allowing us classify new signals nominal , faulty . present model extensions enable adaptation changes underlying process , i.e. , concept drift , well transfer learning techniques enable training anomaly detectors new process recipes less data . proposed methods tested historical data plasma etch ion implantation processes , outperforming benchmark methods including traditional statistical process control ( SPC ) , one-class support vector machine ( OC-SVM ) , variational auto-encoder ( VAE ) based detectors . 2022 anomalies anomaly detection faults fault detection one-class classification ion implantation kernel density estimation plasma etch time series C. I. Lang F. -K. Sun B. Lawler J. Dillon . A. Dujaili P. Cardillo P. Alfred A. Bowers A. Mckiernan D. S. Boning",J. Ruth,0,0.8576654
7737,"E.B . Johnson Brain-derived neurotrophic factor cerebrospinal fluid plasma biomarker Huntington 's disease Brain-derived neurotrophic factor ( BDNF ) implicated survival striatal neurons . BDNF function reduced Huntington 's disease ( HD ) , possibly mutant huntingtin impairs cortico-striatal transport , contributing striatal neurodegeneration . BDNF trophic pathway therapeutic target , blood BDNF suggested potential biomarker HD , BDNF quantified cerebrospinal fluid ( CSF ) HD . quantified BDNF CSF plasma HD-CSF cohort ( 20 pre-manifest 40 manifest HD mutation carriers 20 age gender-matched controls ) using conventional ELISAs ultra-sensitive immunoassay . BDNF concentration limit detection conventional ELISAs , raising doubt previous CSF reports neurodegeneration . Using ultra-sensitive method , BDNF concentration quantifiable samples differ controls HD mutation carriers CSF plasma , associated clinical scores MRI brain volumetric measures , poor ability discriminate controls HD mutation carriers , premanifest manifest HD . conclude BDNF CSF plasma unlikely biomarker HD progression urge caution interpreting studies conventional ELISA used quantify CSF BDNF . 2021.0 Ou , ZYA Byrne , LM Rodrigues , FB Tortelli , R Foiani , MS Arridge , De Vita , E Scahill , RI Heslegrave , Zetterberg , H Wild , EJ",E.B. Johnson,"Johnson , Eileanoir B . Multi-Study Model-Based Evaluation Sequence Imaging Clinical Biomarker Changes Huntington 's Disease Understanding order progression change biomarkers neurodegeneration essential detect effects pharmacological interventions biomarkers . Huntington 's disease ( HD ) , motor , cognitive MRI biomarkers currently used clinical trials drug efficacy . first time use directly compare data three large observational studies HD ( total N = 532 ) using probabilistic event-based model ( EBM ) characterise order motor , cognitive MRI biomarkers become abnormal . also investigate impact genetic cause HD , cytosine-adenine-guanine ( CAG ) repeat length , progression stages . find EBM uncovers broadly consistent order events across three studies ; EBM stage reflects clinical stage ; EBM stage related age genetic burden . findings indicate measures subcortical white matter volume become abnormal prior clinical cognitive biomarkers . Importantly , CAG repeat length large impact timing onset stage progression stages , longer repeat length resulting earlier onset faster progression . results used help design clinical trials treatments Huntington 's disease , influencing choice biomarkers recruitment participants . 2021.0 huntington 's disease biomarkers disease progression model multi-study investigation clinical staging Wijeratne , PA Gregory , Georgiou-Karistianis , N Paulsen , JS Scahill , RI Tabrizi , SJ Alexander , DC","Johnson, Eileanoir B.",1,0.94674736
9771,"A.N . Fonteh Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , King , KS Chui , H Pogoda , JM Harrington , MG",A.N. Fonteh,"Fonteh , Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Fonteh, AN",1,0.8869579
5033,"Su , L Epigenomic analysis 5-hydroxy-methylcytosine ( 5hmC ) reveals novel DNA methylation markers lung cancers Background : DNA methylation fifth position cytosine ( 5mC ) common epigenetic alteration affecting range cellular processes . recent years , 5-hydroxymethylcytosine ( 5hmC ) , oxidized form 5mC , risen broad interests potential biomarker lung cancer diagnosis survival . Methods : analyzed epigenome-wide 5hmC profiles paired lung tumor adjacent normal tissues , using TET-Assisted Bisulfite ( TAB ) array - Infinium MethylationEPIC BeadChip ( EPIC ) approach . differentially methylated CpG sites identified , biological relevance 5hmC assessed differential methylation regions ( DMR ) analysis gene set analysis ( GSA ) . Results : observed global hypomethylation 5hmC comparing tumor normal tissues , hypermethylated 5hmC enriched CpG islands gene upstream . Comparison 5hmC 5modC ( total methylation : 5mC + 5hmC ) profiling showed low correlation , small proportion significant 5hmC loci overlapped significant total methylation loci . GSA analysis suggested 5hmC mainly involved biological processes cellular process , biological regulation , metabolic process . Conclusion : first study analyze epigenome-wide 5hmC profiles among paired lung tumor normal tissues . observed global hypomethylation 5hmC lung cancers , hypermethylated 5hmC enriched CpG islands gene upstream . found genome-wide 5hmC levels correlate total methylation , GSA suggested different biological functions 5hmC compared 5modC . Overall , results demonstrate potential 5hmC novel biomarker lung cancer . 2020.0 lung neoplasms epigenomics biomarkers methylation 5-hydroxymethylcytosine Wang , ZH Du , ML Yuan , QY Guo , YC Hutchinson , JN Zheng , YN Wang , J Mucci , LA Lin , XH Hou , LF Christiani , DC","Su, L","Sodhi , K Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Lakhani , HV Tirona , MT Thompson , E","Sodhi, K",0,0.9075206
10840,"Samieri , C Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Scarmeas , N Bowman , GL","Samieri, C","Anderson , LM Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Gordon , B Southwell , AL Hayden , MR","Anderson, LM",0,0.8693159
12210,"Anderson , LM Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Gordon , B Southwell , AL Hayden , MR","Anderson, LM","Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J",0,0.92097414
8692,"Singh , Oxidized HDL , Adipokines , Endothelial Dysfunction : Potential Biomarker Profile Cardiovascular Risk Women Obesity Objective High BMI predicts adverse cardiovascular outcomes positively correlates increased levels adipokines . relationship among BMI , IL-6 , TNF alpha , adiponectin , oxidized high-density lipoprotein ( Ox-HDL ) circulating endothelial cells ( CECs ) endothelial progenitor cells ( EPCs ) well studied . Elevated CEC levels described humans mice obesity diabetes . Ox-HDL shown potent driver adipogenesis vivo vitro . study , elevated BMI examined 2 groups women studied Brooklyn , New York , Huntington , West Virginia , respectively . Methods Twenty-six females obesity five lean controls without overt cardiovascular disease enrolled , 13 Huntington 13 Brooklyn . Cytokine levels , EPCs , CECs determined . Results Females obesity elevated levels leptin , IL-6 , Ox-HDL , increased CEC levels , decreased EPC adiponectin levels ( P < 0.01 ) . Ox-HDL levels higher women Brooklyn versus Huntington ( P < 0.01 ) , possibly higher TNF alpha levels Brooklyn higher adiponectin levels Huntington . Seventy-five percent variance Ox-HDL levels could predicted population ( P < 0.01 ) . Conclusions study reveals unique inflammatory biomarker profile females obesity . 2019.0 Peterson , SJ Shapiro , JI Thompson , E Liu , L Weingarten , JA O'Hanlon , K Bialczak , Bhesania , SR Abraham , NG","Singh, S","Lakhani , HV Biomarker panel early screening trastuzumab -induced cardiotoxicity among breast cancer patients west virginia Cardiotoxicity well-known pathophysiological consequence breast cancer patients receiving trastuzumab . Trastuzumab related cardiotoxicity typically results overall decline cardiac function , primarily characterized reduction left ventricular ejection fraction ( LVEF ) development symptoms associated heart failure . Current strategies monitoring cardiac function , trastuzumab therapy , includes serial echocardiography , cost ineffective well offers limited specificity , offering limited potential monitoring early onset cardiotoxicity . However , biomarkers shown aberrant prior detectable functional clinical deficit cardiac function . Hence , study aims develop panel novel biomarkers circulating miRNAs early screening trastuzumab induced cardiotoxicity . Patients clinical diagnosis invasive ductal carcinoma enrolled study , blood specimen collected echocardiography performed prior trastuzumab therapy initiation baseline , 3- 6-months post trastuzumab therapy . Following 6-months trastuzumab therapy , 18 % subjects developed cardiotoxicity , defined reduction LVEF . results showed significant upregulation biomarkers circulating miRNAs , specific cardiac injury remodeling , 3- 6-months post trastuzumab therapy . biomarkers circulating miRNAs significantly correlated cardiac injury specific markers , troponin T. findings present study demonstrates translational applicability proposed biomarker panel early preclinical diagnosis trastuzumab induced cardiotoxicity , allowing management cardiac function decline improved health outcomes breast cancer patients . 2022.0 cardiotoxicity chemotherapy biomarkers cardiac dysfunction microrna breast cancer Pillai , SS Pereira , DG Bonsu , G Chaudhry , H Puri , N Tirona , MT Sodhi , K Thompson , E","Lakhani, HV",0,0.91494805
10455,"Harrington , MG Evidence blood-CSF barrier transport , inflammatory biomarkers , change migraine , CSF sVCAM1 associates migraine frequency CSF fibrinogen Objective objective explore whether blood-cerebrospinal fluid ( CSF ) barrier biomarkers differ episodic migraine ( EM ) chronic migraine ( CM ) controls . Background Reports blood-brain barrier blood-cerebrospinal fluid barrier ( BCSFB ) disruption migraine vary . hypothesis investigation biomarkers associated blood , CSF , brain , cell adhesion , inflammation help elucidate migraine pathophysiology . Methods recruited 14 control volunteers without headache disorders 42 individuals EM CM classified using International Classification Headache Disorders , 3rd edition , criteria cross-sectional study located Pasadena Stanford headache research centers California . Blood lumbar CSF samples collected diagnosed CM EM two states : typical migraine , rescue therapy , least 6/10 level pain ( ictal ) ; migraine free least 48 h ( interictal ) . average number headaches per month previous year estimated EM ; enabled comparison biomarker changes controls three headache frequency groups : < 2 per month , 2-14 per month , CM . Blood CSF biomarkers determined using antibody-based methods . Results Antimigraine medication taken EM CM groups . Compared controls , migraine group significantly higher mean CSF-blood quotients albumin ( Q ( alb ) : mean +/- standard deviation ( SD ) : 5.6 +/- 2.3 vs. 4.1 +/- 1.9 ) fibrinogen ( Q ( fib ) mean +/- SD : 1615 +/- 99.0 vs. 86.1 +/- 55.0 ) . Mean CSF plasma soluble vascular cell adhesion molecule-1 ( sVCAM-1 ) levels significantly higher frequent migraine : ( 4.5 ng/mL +/- 1.1 < 2 headache days month ; 5.5 +/- 1.9 2-14 days month ; 7.1 +/- 2.9 CM ) , Q ( fib ) ratio inversely related headache frequency . find difference individuals EM CM controls CSF cell count , total protein , matrix metalloproteinase-9 , soluble platelet-derived growth factor receptor beta , tumor necrosis factor-alpha , interferon-gamma , interleukin ( IL ) -6 , IL-8 , IL-10 , C-reactive protein . Conclusions higher Q ( alb ) Q ( fib ) ratios may indicate transport blood-derived proteins disturbed BCSFB persons migraine . changes likely occur choroid plexus epithelium , signs typical endothelial barrier disruption . striking finding hypothesis-generating study migraine pathophysiology sVCAM-1 levels CSF may biomarker higher frequency migraine CM . effect migraine medications excluded , known mechanism suggest role altering CSF biomarkers . 2021.0 albumin quotient chronic migraine cytokines headache frequency ictal migraine soluble vascular cell adhesion molecule & # 8208 1 Cowan , RP Gross , NB Sweeney , MD Sagare , AP Montagne , Arakaki , X Fonteh , Zlokovic , BV Pogoda , JM","Harrington, MG","Byrne , LM Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Byrne, LM",0,0.9172101
498,"Y. Su Joint Task Offloading Resource Allocation Accuracy-Aware Machine-Learning-Based IIoT Applications Machine learning ( ML ) plays key role Intelligent Industrial Internet Things ( IIoT ) applications . Processing computation-intensive ML tasks largely enhanced applying edge computing ( EC ) traditional cloud-based schemes . System optimizations existing works always ignore inference accuracy ML models different complexities , impacts error task inference . article , propose joint task offloading resource allocation scheme accuracy-aware machine-learning-based IIoT applications edge���cloud-based network architecture . aim minimizing long-term average system cost affected task offloading , computing resource allocation , inference accuracy ML models deployed sensors , edge server , cloud server . Lyapunov optimization technique applied convert long-term stochastic optimization problem short-term deterministic problem . optimal algorithm based general Benders decomposition ( GBD ) technology heuristic algorithm based proportional computing resource allocation task offloading strategy comparison proposed efficiently solve problem , respectively . performance scheme proved theoretical analysis evaluated extensive simulations conducted multiple scenarios . Simulation results demonstrate effectiveness superiority two algorithms comparison several schemes proposed existing works . 2023 cloud computing edge computing ( ec ) machine learning ( ml ) resource allocation task offloading W. Fan S. Li J. Liu F. Wu Y. Liu",Y. Su,"R. Jin Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network Z. Chen K. Wu M. Wu X. Li R. Yan",R. Jin,0,0.9466602
1401,"A. Borghesi Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning M. Molan M. Milano A. Bartolini",A. Borghesi,"Black , Hailey Findlay Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Banos , R Aly , AE Xie , YY Ko , Potluri , N Anderson , C Anderson , LM Gordon , B Southwell , AL Hayden , MR","Black, Hailey Findlay",0,0.8281519
10994,"Albensi , BC Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Gibson , GE Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Albensi, BC","S. Wu Image Reconstruction Based Multilevel Densely Connected Network Threshold Electrical Capacitance Tomography Electrical capacitance tomography ( ECT ) real-time monitoring technology visualization industrial dynamic processes . Due inherent nonlinearity ill-posed nature ECT inverse problem , achieving fast accurate image reconstruction remains great challenge . novel multilevel densely connected network channelwise thresholds ( MDCN-CW ) proposed , adopts deep-learning framework implement reconstruction process similar iterative algorithms . MDCN-CW highly condensed framework achieves efficient information transfer dense connections within subnetworks , soft thresholding inserted subnetwork nonlinear transformation layer eliminate unimportant features . Matching purpose structure MDCN-CW , phased strategy used train . subnetwork first trained stepwise individual strategy , network parameters fine-tuned subnetworks integrated improve overall fit model . Simulation experimental results show , compared existing deep-learning-based reconstruction methods traditional algorithms , proposed ECT image reconstruction network soft thresholds advantages simple structure , high imaging accuracy , good generalization ability . 2022 channelwise threshold deep learning dense connection electrical capacitance tomography ( ect ) image reconstruction Z. Wang L. Zhang B. Zhang J. Zhao",S. Wu,0,0.81833684
2443,"S. Wu Image Reconstruction Based Multilevel Densely Connected Network Threshold Electrical Capacitance Tomography Electrical capacitance tomography ( ECT ) real-time monitoring technology visualization industrial dynamic processes . Due inherent nonlinearity ill-posed nature ECT inverse problem , achieving fast accurate image reconstruction remains great challenge . novel multilevel densely connected network channelwise thresholds ( MDCN-CW ) proposed , adopts deep-learning framework implement reconstruction process similar iterative algorithms . MDCN-CW highly condensed framework achieves efficient information transfer dense connections within subnetworks , soft thresholding inserted subnetwork nonlinear transformation layer eliminate unimportant features . Matching purpose structure MDCN-CW , phased strategy used train . subnetwork first trained stepwise individual strategy , network parameters fine-tuned subnetworks integrated improve overall fit model . Simulation experimental results show , compared existing deep-learning-based reconstruction methods traditional algorithms , proposed ECT image reconstruction network soft thresholds advantages simple structure , high imaging accuracy , good generalization ability . 2022 channelwise threshold deep learning dense connection electrical capacitance tomography ( ect ) image reconstruction Z. Wang L. Zhang B. Zhang J. Zhao",S. Wu,"Edminster , SP Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Tran , King , KS Chui , H Pogoda , JM Fonteh , Harrington , MG","Edminster, SP",0,0.8273325
1286,"Andrea Bartolini Anomaly Detection Anticipation High Performance Computing Systems quest toward Exascale , High Performance Computing ( HPC ) systems rapidly becoming larger complex , together issues concerning maintenance . Luckily , many current HPC systems endowed data monitoring infrastructures characterize system state , whose data used train Deep Learning ( DL ) anomaly detection models , popular research area . However , lack labels describing state system wide-spread issue , annotating data costly task , generally falling human system administrators thus scale toward exascale . article investigate possibility extract labels service monitoring tool ( Nagios ) currently used HPC system administrators flag nodes undergo maintenance operations . allows automatically annotate data collected fine-grained monitoring infrastructure ; labelled data used train validate DL model anomaly detection . conduct experimental evaluation tier-0 production supercomputer hosted CINECA , Bologna , Italy . results reveal DL model accurately detect real failures , , moreover , predict insurgency anomalies , systematically anticipating actual labels ( i.e. , moment system administrators realize anomalous event happened ) ; average advance time computed historical traces around 45 minutes . proposed technology easily scaled toward exascale systems easy maintenance . 2022 high performance computing anomaly detection deep learning A. Borghesi M. Molan M. Milano",Andrea Bartolini,"Banos , R Cerebrospinal fluid mutant huntingtin biomarker huntingtin lowering striatum Huntington disease mice Huntington disease ( HD ) neurodegenerative disease caused trinucleotide repeat expansion HTT gene encoding elongated polyglutamine tract huntingtin ( HTT ) protein . Expanded mutant HTT ( mHTT ) toxic leads regional atrophy neuronal cell loss brain , occurs earliest striatum . Therapeutic lowering mHTT central nervous system ( CNS ) shown promise preclinical studies , multiple approaches currently clinical development HD . Quantitation mHTT cerebrospinal fluid ( CSF ) used clinical pharmacodynamic biomarker target engagement CNS . previously shown CNS major source mHTT CSF . However , little known specific brain regions cell types contribute CSF mHTT . Therefore , better understanding origins CSF mHTT whether therapies targeting mHTT striatum would expected associated significant lowering mHTT CSF needed . , use complementary pharmacological genetic-based approaches either restrict expression mHTT striatum selectively deplete mHTT striatum evaluate contribution brain region mHTT CSF . show viral expression mHTT fragment restricted striatum leads detectable mHTT CSF . demonstrate targeted lowering mHTT selectively striatum using antisense oligonucleotide leads significant reduction mHTT CSF HD mice . Furthermore , using transgenic mouse model HD expresses full length human mHTT wild type HTT , show genetic inactivation mHTT selectively striatum results significant reduction mHTT CSF . Taken together , data supports conclusion striatum contributes sufficiently pool mHTT CSF therapeutic levels mHTT lowering striatum detected measure HD mice . suggests CSF mHTT may represent pharmacodynamic biomarker therapies lower mHTT striatum . 2022.0 huntington disease biomarker neurodegeneration huntingtin cerebrospinal fluid antisense oligonucleotide Caron , NS Aly , AE Xie , YY Ko , Potluri , N Anderson , C Black , HF Anderson , LM Gordon , B Southwell , AL Hayden , MR","Banos, R",0,0.83413064
2680,"J. Cui Partial Transfer Learning Multidiscriminator Deep Weighted Adversarial Network Cross-Machine Fault Diagnosis Deep transfer learning provides feasible fault diagnosis method intelligent mechanical systems . However , method usually assumes source domain target domain label space , greatly limits application actual industry . Therefore , article proposes multidiscriminator deep weighted adversarial network ( MDWAN ) method , especially suitable partial transfer learning number target domain categories less source domain . proposed method mainly composed three parts : feature extractor , multidiscriminator , classifier . feature extraction section , deep separable convolutional neural network model ( DSC ) proposed , greatly reduce parameter calculation amount premise ensuring extraction accuracy . multidiscriminator section , multidiscriminator weighted learning strategy proposed . strategy comprehensively considers domain information source domain label information , introduces weight function quantify contribution source domain samples domain discriminator classifier , effectively identify filter outlier source samples promote positive transfer shared samples . order verify effectiveness feasibility proposed method , method applied three types bearing datasets different machines . Comparing classification results different methods , conclusion shows method beneficial bearing fault classification . 2022 adversarial network cross-machine fault diagnosis multidiscriminator partial transfer learning Z. Wang W. Cai Y. Li",J. Cui,"Harrington , M. G. Accumulation Cerebrospinal Fluid Glycerophospholipids Sphingolipids Cognitively Healthy Participants Alzheimer 's Biomarkers Precedes Lipolysis Dementia Stage Insight lipids ' roles Alzheimer 's disease ( AD ) pathophysiology limited brain membrane lipids characterized cognitively healthy ( CH ) individuals . Since age significant risk factor AD , hypothesize aging renders amyloid precursor protein ( APP ) susceptible abnormal processing deteriorating membrane lipids . reflect brain membranes , studied lipid components cerebrospinal fluid ( CSF ) brain-derived CSF nanoparticle membranes . Based CSF beta ( 42 ) /Tau levels established biomarkers AD , define subset CH participants normal beta ( 42 ) /Tau ( CH-NAT ) another group abnormal pathological beta ( 42 ) /Tau ( CH-PAT ) . report glycerophospholipids differentially metabolized CSF supernatant fluid nanoparticle membrane fractions CH-NAT , CH-PAT , AD participants . Phosphatidylcholine molecular species supernatant fraction CH-PAT higher CH-NAT AD participants . Sphingomyelin levels supernatant fraction lower CH-PAT AD CH-NAT group . decrease sphingomyelin corresponded increase ceramide dihydroceramide increase ceramide sphingomyelin ratio AD . contrast supernatant fraction , sphingomyelin higher nanoparticle fraction CH-PAT group , accompanied lower ceramide dihydroceramide decrease ratio ceramide sphingomyelin CH-PAT compared CH-NAT . investigating mechanism lipid changes AD , observed phospholipase ( 2 ) ( PLA ( 2 ) ) activity higher AD group CH groups . Paradoxically , acid neutral sphingomyelinase ( SMase ) activities lower AD compared CH groups . Considering external influences lipids , clinical groups differ fasting blood lipids dietary lipids , consistent CSF lipid changes originating brain pathophysiology . lipid accumulation prodromal AD biomarker positive stage identifies perturbation lipid metabolism disturbances APP/Amyloid beta ( beta ) early events AD pathophysiology . results identify increased lipid turnover CH participants AD biomarkers , switching predominantly lipolytic state dementia . knowledge may useful targeting testing new AD treatments . 2020.0 alzheimer & # 8217 disease biomarker amyloid cerebrospinal fluid dementia glycerophospholipids nanoparticles sphingolipids tau Fonteh , Chiang , AJ Arakaki , X Edminster , SP","Harrington, M. G. ",0,0.80390155
3257,"R. Jin Bi-LSTM-Based Two-Stream Network Machine Remaining Useful Life Prediction industry , prognostics health management ( PHM ) used improve system reliability efficiency . PHM , remaining useful life ( RUL ) prediction plays key role preventing machine failure reducing operation cost . Recently , development deep learning technology , long short-term memory ( LSTM ) convolutional neural networks ( CNNs ) adopted many RUL prediction approaches , shows impressive performances . However , existing deep learning-based methods directly utilize raw signals . Since noise widely exists raw signals , quality approaches��� feature representation degraded , degenerates RUL prediction accuracy . address issue , first propose series new handcrafted feature flows ( HFFs ) , suppress raw signal noise thus improve encoded sequential information RUL prediction . addition , effectively integrate proposed HFFs raw input signals , novel bidirectional LSTM ( Bi-LSTM ) -based two-stream network proposed . novel two-stream network , three different fusion methods designed investigate combine streams��� feature representations reasonable way . verify proposed Bi-LSTM-based two-stream network , extensive experiments carried commercial modular aero propulsion system simulation ( C-MAPSS ) dataset , showing superior performances state-of-the-art approaches . 2022 bidirectional lstm ( bi-lstm ) deep learning remaining useful life ( rul ) prediction time series two-stream network Z. Chen K. Wu M. Wu X. Li R. Yan",R. Jin,"Lowe , AJ Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Zetterberg , H Wild , EJ","Lowe, AJ",0,0.85463524
5955,"Wild , EJ Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Parker , C Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Wild, EJ","Wild , Edward J Mutant huntingtin neurofilament light distinct longitudinal dynamics Huntington 's disease longitudinal dynamics promising biofluid biomarker candidates Huntington 's disease ( HD ) -mutant huntingtin ( mHTT ) neurofilament light ( NfL ) -are incompletely defined . Characterizing changes candidates disease progression could increase understanding disease pathophysiology help identification effective therapies . 80-participant cohort 24 months , mHTT cerebrospinal fluid ( CSF ) , well NfL CSF blood , distinct longitudinal trajectories HD mutation carriers compared controls . Baseline analyte values predicted clinical disease status , subsequent clinical progression , brain atrophy , better rate change analytes . Overall , NfL stronger monitoring prognostic biomarker HD mHTT . Nonetheless , mHTT prognostic value might valuable pharmacodynamic marker huntingtin-lowering trials . 2020.0 Rodrigues , FB Byrne , LM Tortelli , R Johnson , EB Wijeratne , PA Arridge , De Vita , E Ghazaleh , N Houghton , R Furby , H Alexander , DC Tabrizi , SJ Schobel , Scahill , RI Heslegrave , Zetterberg , H","Wild, Edward J",1,0.9131129
8315,"Zetterberg , Henrik Longitudinal evaluation proton magnetic resonance spectroscopy metabolites biomarkers Huntington 's disease study Lowe et al . uses magnetic resonance spectroscopy investigate biomarker potential neurochemical metabolites Huntington 's disease . Cross-sectional associations observed metabolites prognostic measures ; however , absence consistent group differences lack clear longitudinal change indicates limited biomarker potential Huntington 's disease . Proton magnetic resonance spectroscopy non-invasive method exploring cerebral metabolism . Huntington 's disease , altered proton magnetic resonance spectroscopy-determined concentrations several metabolites described ; however , findings often discrepant longitudinal studies lacking . Proton magnetic resonance spectroscopy metabolites may represent source biomarkers , thus relationship established markers disease progression require exploration assess prognostic value elucidate pathways associated neurodegeneration . prospective single-site controlled cohort study standardized collection CSF , blood , phenotypic volumetric imaging data , used 3 proton magnetic resonance spectroscopy conjunction linear combination model spectra method quantify seven metabolites ( total n-acetylaspartate , total creatine , total choline , myo-inositol , GABA , glutamate glutathione ) putamen 59 participants baseline ( 15 healthy controls , 15 premanifest 29 manifest Huntington 's disease gene expansion carriers ) 48 participants 2-year follow-up ( 12 healthy controls , 13 premanifest 23 manifest Huntington 's disease gene expansion carriers ) . Intergroup differences concentration associations CSF plasma biomarkers ; including neurofilament light chain mutant Huntingtin , volumetric imaging markers ; namely whole brain , caudate , grey matter white matter volume , measures disease progression cognitive decline , assessed cross-sectionally using generalized linear models partial correlation . report significant groupwise differences metabolite concentration baseline found total creatine total n-acetylaspartate significantly reduced manifest compared premanifest participants follow-up . Additionally , total creatine myo-inositol displayed significant associations reduced caudate volume across time points gene expansion carriers . Although relationships observed proton magnetic resonance spectroscopy metabolites biofluid measures , consistent across time points . assess prognostic value , examined whether baseline proton magnetic resonance spectroscopy values , rate change , predicted subsequent change established measures disease progression . Several associations found inconsistent across known indicators disease progression . Finally , longitudinal mixed-effects models revealed glutamine + glutamate display slow linear decrease time gene expansion carriers . Altogether , findings show evidence reduced total n-acetylaspartate total creatine disease progresses cross-sectional associations select metabolites , namely total creatine myo-inositol , markers disease progression , potentially highlighting proposed roles neuroinflammation metabolic dysfunction disease pathogenesis . However , absence consistent group differences , inconsistency baseline follow-up , lack clear longitudinal change suggests proton magnetic resonance spectroscopy metabolites limited potential Huntington 's disease biomarkers . 2022.0 biomarkers huntington 's disease magnetic resonance spectroscopy cerebrospinal fluid Lowe , AJ Rodrigues , FB Arridge , De Vita , E Johnson , EB Scahill , RI Byrne , LM Tortelli , R Heslegrave , Wild , EJ","Zetterberg, Henrik","Parker , C Biological clinical characteristics gene carriers far predicted onset Huntington ? disease Young Adult Study ( HD-YAS ) : cross-sectional analysis Background Disease-modifying treatments development Huntington 's disease ; crucial success identify timepoint patient 's life measurable biomarker early neurodegeneration clinical function still intact . aimed identify timepoint novel cohort young adult premanifest Huntington 's disease gene carriers ( preHD ) far predicted clinical symptom onset . Methods Huntington 's disease Young Adult Study ( HD-YAS ) UK . recruited young adults preHD controls matched age , education , sex ensure group least 60 participants imaging data , accounting scan fails . Controls either family history Huntington 's disease negative genetic test , known family history Huntington 's disease . participants underwent detailed neuropsychiatric cognitive assessments , including tests Cambridge Neuropsychological Test Automated Battery battery assessing emotion , motivation , impulsivity social cognition ( EMOTICOM ) . Imaging ( done participants without contraindications ) included volumetric MRI , diffusion imaging , multiparametric mapping . Biofluid markers neuronal health examined using blood CSF collection . cross-sectional analysis using general least-squares linear models assess group differences associations age CAG length , relating predicted years clinical onset . Results corrected multiple comparisons using false discovery rate ( FDR ) , FDR < 0.05 deemed significant result . Findings Data obtained Aug 2 , 2017 , April 25 , 2019 . recruited 64 young adults preHD 67 controls . Mean ages participants 29.0 years ( SD 5.6 ) 29.1 years ( 5.7 ) preHD control groups , respectively . noted significant evidence cognitive psychiatric impairment preHD participants 23.6 years ( SD 5.8 ) predicted onset ( FDR 0.22-0.87 cognitive measures , 0.31-0.91 neuropsychiatric measures ) . preHD cohort slightly smaller putamen volumes ( FDR=0.03 ) , appear closely related predicted years onset ( FDR=0.54 ) . group differences brain imaging measures ( FDR > 0.16 ) . CSF neurofilament light protein ( NfL ) , plasma NfL , CSF YKL-40 elevated far-from-onset preHD cohort compared controls ( FDR < 0.0001 , =0.01 , =0.03 , respectively ) . CSF NfL elevations likely individuals closer expected clinical onset ( FDR < 0.0001 ) . Interpretation report normal brain function yet rise sensitive measures neurodegeneration preHD cohort approximately 24 years predicted clinical onset . CSF NfL appears sensitive measure plasma NfL monitor disease progression . preHD cohort one earliest yet studied , findings could used inform decisions initiate potential future intervention delay prevent neurodegeneration function intact . 2020.0 Scahill , RI Zeun , P Osborne-Crowley , K Johnson , EB Gregory , Lowe , J Nair , O'Callaghan , C Langley , C Papoutsi , McColgan , P Estevez-Fraga , C Fayer , K Wellington , H Rodrigues , FB Byrne , LM Heselgrave , Hyare , H Sampaio , C Zetterberg , H Zhang , H Wild , EJ Rees , G Robbins , TW Sahakian , BJ Langbehn , Tabrizi , SJ","Parker, C",0,0.9364292
11175,"Gibson , GE Nutritional metabolism cerebral bioenergetics Alzheimer 's disease related dementias Disturbances brain 's capacity meet energy demand increase risk synaptic loss , neurodegeneration , cognitive decline . Nutritional metabolic interventions target metabolic pathways combined diagnostics identify deficits cerebral bioenergetics may therefore offer novel therapeutic potential Alzheimer 's disease ( AD ) prevention management . Many diet-derived natural bioactive components govern cellular energy metabolism effects brain aging clear . review examines nutritional metabolism regulate brain bioenergetics mitigate AD risk . focus leading mechanisms cerebral bioenergetic breakdown aging brain cellular level , well putative causes consequences disturbed bioenergetics , particularly blood-brain barrier implications nutrient brain delivery nutritional interventions . Novel therapeutic nutrition approaches including diet patterns provided , integrating studies gut microbiome , neuroimaging , biomarkers guide future personalized nutritional interventions . None Yassine , HN Self , W Kerman , Santoni , G Shanmugam , NN Abdullah , L Golden , LR Fonteh , Harrington , MG Graff , J Kalaria , R Luchsinger , JA Feldman , HH Swerdlow , RH Johnson , LA Albensi , BC Zlokovic , BV Tanzi , R Cunnane , Samieri , C Scarmeas , N Bowman , GL","Gibson, GE","King , Kevin S. Urine dicarboxylic acids change pre-symptomatic Alzheimer 's disease reflect loss energy capacity hippocampal volume Non-invasive biomarkers enable widespread screening early diagnosis Alzheimer 's disease ( AD ) . hypothesized considerable loss brain tissue AD result detection brain lipid components urine , change concert CSF brain biomarkers AD . examined urine dicarboxylic acids ( DCA ) carbon length 3-10 reflect products oxidative damage energy generation balance may account changes brain function AD . Mean C4-C5 DCAs lower mean C7-C10 DCAs higher urine AD compared cognitively healthy ( CH ) individuals . Moreover , mean C4-C5 DCAs lower mean C7-C9 higher urine CH individuals abnormal compared normal CSF amyloid Tau levels ; i.e. , apparent urine changes AD also appeared present CH individuals CSF risk factors early AD pathology . examining relationship urine DCAs AD biomarkers , found short chain DCAs positively correlated CSF beta 42 , C7-C10 DCAs negatively correlated CSF beta 42 positively correlated CSF Tau levels . Furthermore , found negative correlation C7-C10 DCAs hippocampal volume ( p < 0.01 ) , found occipital volume . Urine measures DCAs 82 % ability predict cognitively healthy participants normal CSF amyloid/Tau . data suggest urine measures increased lipoxidation dysfunctional energy balance reflect early AD pathology brain CSF biomarkers . Measures urine DCAs may contribute personalized healthcare indicating AD pathology may utilized explore population wellness monitor efficacy therapies clinical trials . 2020.0 Castor , KJ Shenoi , Edminster , SP Tran , Chui , H Pogoda , JM Fonteh , Harrington , MG","King, Kevin S.",0,0.8853637
